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Hepatic metabolic dysregulation has been shown to induce fatty liver, insulin 
resistance and obesity. The retinoic acid receptor-related orphan receptor  (ROR) 
is an important regulator of various biological processes, including cerebellum 
development, circadian rhythm, and cancer. Here, I find that hepatic ROR 
regulates lipid homeostasis by negatively regulating transcriptional activity of 
peroxisome proliferators-activated receptor  (PPAR), a nuclear receptor that 
mediates hepatic lipid metabolism. Liver-specific Ror deficient mice develop 
hepatic steatosis, obesity, and insulin resistance, when challenged with a high fat 
diet (HFD). Global transcriptome analysis reveals that liver-specific deletion of 
Ror leads to the dysregulation of PPAR signaling to increase hepatic glucose and 
lipid metabolism. ROR specifically binds and recruits HDAC3 to the PPAR target 
promoters for the transcriptional repression of PPAR activity. Finally, PPAR 
antagonism remarkably restores metabolic homeostasis in HFD-fed liver-specific 
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Ror deficient mice. Taken together, my data indicate that ROR plays a pivotal 
role in the regulation of hepatic lipid homeostasis. Therefore, therapeutic strategies 
designed to modulate ROR activity may be beneficial for the treatment of 
metabolic disorders, including hepatic steatosis and obesity.   
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I-1. Orphan Nuclear Receptors and ROR 
 
1.1 General information of orphan nuclear receptors 
  The nuclear receptor superfamily plays many important roles in development, 
differentiation, reproduction and metabolic homeostasis (Bain et al., 2007; Ribeiro et al., 
1995). Nuclear receptors are composed of independent functional domains that include the 
amino-terminal domain (NTD), the DNA-binding domain (DBD) and Ligand-binding 
domain (LBD) (Giguere, 1999). Nuclear receptors are receptors for physiological ligands, 
including steroid hormones, lipids and fatty acids (Kojetin and Burris, 2014) (Fig. I-1). 
However, the orphan nuclear receptor family comprises a set of proteins sharing significant 
sequence homology to known nuclear receptors, but for which the ligands have not yet been 
identified (Giguere, 1999). Similar to the other members of nuclear receptors, orphan 
nuclear receptors are composed of functional domains that include the DBD and the LBD 
(Aranda and Pascual, 2001).  
 
1.2 Structure of orphan nuclear receptors 
  The amino-terminal domain (NTD), also referred to as the modulator domain, shows the 
most flexibility domain both in terms of sequence length and primary sequence (Wang and 
Sadar, 2006). The NTD shows promoter- and cell-specific activity, suggesting that it is 
likely to contribute to the specificity of function (Shao and Lazar, 1999). The DNA-binding 
domain (DBD) confers the ability to recognize specific target sequences and activate genes. 
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This is the most highly conserved region of the orphan nuclear receptor, and its interactions 
with DNA have been well characterized (Zilliacus et al., 1995). The DBD contains nine 
cysteines, as well as other residues that are conserved across the nuclear receptor 
superfamily and are required for high-affinity DNA binding (Weatherman et al., 1999). The 
Ligand-binding domain (LBD) is a multifunctional domain that mediates binding of ligand, 
homo- and hetero- dimerization, interaction with co-regulator proteins, transactivation 
functions (Dubbink et al., 2006). The LBD is folded into a three-layered, antiparallel helical 
sandwich. A central core layer of three helices is packed between two additional layers to 
create a cavity, the ligand-binding pocket, which accommodates the ligand. This domain is 
mainly hydrophobic and is buried within the bottom half of the LBD. Contacts with the 
ligand can be extensive and include different structural elements through the LBD (Moras 
and Gronemeyer, 1998). However, the orphan nuclear receptor family has no defined 





Figure I-1. Illustration of orphan nuclear receptor structure 
Orphan nuclear receptors are composed of independent functional domains that include the 
NTD, DBD and LBD. The NTD that located at the amino termini has transcription 
activation function. The DBD has the functions of which are to recognize specific DNA 






1.3 General information of ROR 
  The retinoic acid receptor (RAR)-related orphan receptor  (ROR) is a member of the 
ROR subfamily that composed of ROR, ROR and ROR (Carlberg et al., 1994; Giguere 
et al., 1994). The ROR gene is located in human chromosome 15q22.2 and covers a 
relatively large 730 kb genomic region comprised of 15 exons (Zhu et al., 2006). By the 
alternative splicing mechanism, ROR has four isoforms referring to ROR1 to ROR4 
in human, with different promoters and the NTD region but identical DBD and LBD regions, 
whereas in mice only two isoforms, ROR1 and ROR4 (Becker-Andre et al., 1993; 
Giguere et al., 1994).  
ROR regulates transcription by binding as monomers to ROR response elements 
(RORE), which consist of the core sequence “(A/G)GGTCA” preceded by a 6-bp A/T-rich 
sequence, in the regulatory region of target genes (Giguere et al., 1995). The activation 
function-2 (AF-2) domain that localized at the C-terminus in the LBD is involved in the 
recruitment of co-activators that mediate the transcriptional activation by ROR. PGC1, 
p300, SRC1, SRC2, GRIP1, Tip60, -catenin and CBP have been reported as co-activator 
of ROR by interacting with LBD of ROR (Atkins et al., 1999; Chopra et al., 2008; Gold 
et al., 2003; Harris et al., 2002; Jetten and Joo, 2006). In addition, ROR is widely 
expressed in many tissues, including cerebellar Purkinje cells, the liver, thymus, skeletal 
muscle, skin, lung, adipose tissue and kidney (Hamilton et al., 1996). DNA damage-induced 
expression of ROR leads to stabilize p53 and activates p53 transcription in HAUSP/Usp7-
dependent manner. Interestingly, microarray analysis revealed that ROR-mediated p53 
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stabilization leads to the activation of a subset of p53 target genes that are specifically 
involved in apoptosis (Kim et al., 2011). Therefore, ROR has many regulatory functions 
of various cellular signaling through different combinations with co-activators.  
Post translational modification is important mechanism to regulate transcriptional 
activity of ROR. Phosphorylation by Wnt5a/PKC to serine residue 35 of ROR plays a 
role to link ROR to Wnt/-catenin signaling, and leads to repress expression of Wnt/-
catenin target genes. Interestingly, phosphorylation of ROR is reduced in colorectal tumor 
compared to normal counterpart. ROR has an important role to link the canonical and the 
noncanonical Wnt signaling pathways by attenuating expression of Wnt/-catenin target 
genes (Lee et al., 2010). In addition, methylation by polycomb group Ezh2 to lysine residue 
38 of ROR triggers ubiquitination of ROR permitting to degradation. Methylation of 
lysine residue 38 of ROR is recognized by Cul4/DDB1 E3 ligase complex and caused to 
ubiquitination. Furthermore, upregulation of Ezh2 and downregulation of ROR are 
correlated with each other in breast tumor (Lee et al., 2012). In conclusion, ROR functions 
as tumor suppressor through regulating by post translational modification.  
Staggerer mice that reported in 1962 have a severe cerebellar ataxia because of cell-
autonomous defect in the development of Purkinje cells (Herrup and Mullen, 1979; Sidman 
et al., 1962). In 1996, Staggerer mice were found to have spontaneous ROR deficiency 
(Hamilton et al., 1996). Given that Staggerer mice have huge cerebellar defects, it is still 
possible that physiological changes observed in Staggerer mice are indirect effects. Thus, 
the physiological roles of ROR to control transcriptional networks to modulate other 
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physiological pathway still remain unclear. 
 
1.4 RORin metabolism 
 Staggerer mice are protected against age- and diet- induced obesity and the development 
of several obesity-linked pathologies, including adipose tissue-associated inflammation, 
hepatic steatosis and insulin resistance (Kang et al., 2011; Lau et al., 2011; Lau et al., 2008). 
Despite their higher food consumption, aging Staggerer mice exhibit a reduced body fat 
index. Adipocytes are smaller in brown and white adipose tissue of Staggerer mice than 
WT mice and the level of triglycerides is lower in liver of Staggerer mice than WT mice 
(Lau et al., 2008). Besides, the expression of sterol regulatory element-binding protein 1, 
isoform c (Srebp1c), which is an important regulator of lipogenesis and several lipogenic 
genes like fatty acid synthase (Fas), are significantly reduced in liver and skeletal muscle 
of Staggerer mice (Jetten, 2009; Lau et al., 2008). In addition, the expression of several 
genes involved in the main and alternative pathway of triglyceride synthesis, including 
glycerol-3-phosphate acyltransferase (Gpam), acyl-glycerol-3-phosphate acyltransferase 9 
(Agpat9) and Mono-acyl-glycerol O-Acyl-transferase 1 (Mogat1) were significantly 
diminished in Staggerer mice liver (Kang et al., 2011). However, Staggerer mice has huge 
disadvantage to study metabolism because of cerebellar defect. Staggerer mice show a 
staggering gait and mild tremor, therefore Staggerer mice have eating and drinking 
difficulties. In other words, the reason why obesity does not occur in Staggerer mice is not 
because ROR play a role in promoting obesity, but is simply due to a disturbance of 
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feeding and drinking. In addition, overexpression of ROR in mouse liver by infection with 
adenovirus encoding ROR suppresses the lipid accumulation and protects high fat diet-
induced hepatic steatosis (Kim et al., 2012). Accordingly, studies using specifically 





I-2. Peroxisome proliferator-activated receptor  (PPAR) 
 
2.1  General information of PPAR 
The peroxisome proliferator-activated receptors (PPARs) are members of the nuclear 
receptor superfamily of ligand-inducible transcription factors. In mammals, there are three 
PPARs: PPAR, PPAR/ and PPAR (Evans et al., 2004). PPAR, the first identified 
PPAR, is mainly expressed in liver, heart and brown adipose tissue (BAT) and is the main 
activator of the fatty acid oxidation pathway (Poulsen et al., 2012). PPAR/ functions like 
PPAR but is expressed in ubiquitous and plays an important role in fatty acid oxidation in 
major metabolic tissues such as skeletal muscle, liver and heart (Barish et al., 2006). 
PPAR is abundantly expressed in white adipose tissue (WAT) and BAT, where it is a 
major regulation organ of adipogenesis, as well as a potent regulator of systemic lipid 
metabolism and insulin sensitivity. Because of alternative splicing and differential promoter 
usage, PPAR is present as two isoforms, PPAR1 and PPAR2, with the latter containing 
an additional 30 amino acids at its N terminus (Tontonoz and Spiegelman, 2008). While 
PPAR1 is expressed in many tissues, the expression of PPAR2 is restricted to adipose 
tissue under physiological conditions but can be induced in other tissues by a high-fat diet 
(Medina-Gomez et al., 2007).  
 
2.2 PPAR activators, Thiazolidinediones 
Although fatty acids and their derivatives can activate PPAR, the identification of defined 
endogenous PPAR ligands has been difficult. In contrast, synthetic ligands, 
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Thiazolidinediones (TZDs), are potent activators of PPAR with robust insulin-sensitizing 
activities (Forman et al., 1996). Consequences of highly effective oral medications used in 
the treatment of difficult-to-manage type 2 diabetes that chronically activate PPAR include 
side effect like weight gain, fluid retention and osteoporosis (Nissen and Wolski, 2007). 
Meta-analyses of clinical trials have shown the TZD, especially rosiglitazone, increases the 
risk of congestive heart failure, myocardial infarction, cardiovascular disease and all-cause 
mortality, severely limited accession in the United States and a recommendation for market 
withdrawal in Europe and several other jurisdictions (Wilcox et al., 2008). Thus, a deeper 
understanding of how different TZDs cause an alternative pathway for PPAR activation, 
will potentially lead to new and improved treatments for type 2 diabetes. Recently, in part 
because of powerful new technologies, much progress has been made in understanding the 
signaling, regulation and tissue-specific roles of PPAR (Choi et al., 2011; Dutchak et al., 
2012). Many of these advances provide new insights into the mechanisms of PPAR-
mediated insulin sensitization and related side effects by providing opportunities to develop 
new types of molecules that reduce or eliminate the side effects associated with TZD. TZDs, 
potent lipogenic and antidiabetic ligands that acts by binding and activating PPAR, has 
reinforced the importance of PPAR in insulin sensitization and has facilitated numerous 
studies on this nuclear receptor, PPAR (Agarwal and Garg, 2002; Savage et al., 2003). 
Thus, direct targeting of PPAR remains a 'golden standard' for the treatment of metabolic 





2.3 PPAR in metabolism 
PPAR is originally described as a factor induced during adipocyte differentiation and is 
best known for the regulation of adipogenic and lipogenesis pathways (Tontonoz et al., 
1994). Generation of the PPAR-null mouse, which is completely devoid of adipose tissue, 
firmly established PPAR as a master regulator of adipocyte differentiation (Barak et al., 
1999). PPAR is also essential for mature adipocyte function, and it has been found that 
adipocytes survive only for a few days after selectively depletion of PPAR from mature 
adipocytes (Imai et al., 2004). In addition to its role in adipocyte differentiation and lipid 
metabolism, PPAR is also crucial for controlling gene networks involved in glucose 
homeostasis, including increasing the expression of glucose transporter type 4 (Glut4) and 
c-Cbl–associated protein (CAP). Moreover, PPAR modulates the expression of numerous 
factors secreted from adipose tissue, such as adiponectin, resistin, leptin and tumor necrosis 
factor-α (TNF-α), which also affects insulin sensitivity (Tomaru et al., 2009; Tontonoz and 
Spiegelman, 2008). 
However, the functions of PPAR in the liver and the effects of PPAR agonism on the 
liver remain under debate. Some studies show that PPAR agonists in the liver promote 
hepatic steatosis through upregulation of genes involved in lipid uptake and storage (Way 
et al., 2001). Other studies show that PPAR agonists in the liver prevent hepatic steatosis 
and fibrosis, possibility by sequestering fatty acids in adipose tissue and preventing hepatic 
stellate cell activation (Mayerson et al., 2002; Musso et al., 2012) (Fig. I-2).  
Studies in liver PPAR knockout mice with adipose tissue, showed that they developed 
relative fat intolerance, increased adiposity, hyperlipidemia, and insulin resistance. PPAR 
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exhibits an impaired plasma uptake of triglycerides (TGs) and TG deposition in muscle and 
adipose tissue, which contributes to insulin resistance. Thus hepatic PPAR contributes to 
TG homeostasis, regulating both TG clearance and lipogenesis (Gavrilova et al., 2003) (Fig. 
I-2). 
PPAR is also expressed in pancreatic beta cells, where it induces the expression of major 
genes involved in glucose-stimulated insulin secretion (GSIS), and TZDs improves GSIS 
in insulin-resistant rodents and humans (Higa et al., 1999; Kim et al., 2002). However, 
results from in vivo studies have been conflicting, with one study showing alterations in 
beta-cell mass but no change in glucose homeostasis in beta-cells of PPAR deficient mice 
and recent study showing that knockout of PPAR in the whole pancreas results in 
hyperglycemia with impaired GSIS (Rosen et al., 2003) (Fig. I-2). Taken together, PPAR 
plays an important role in various metabolic organ, but exact metabolic role of PPAR is 






Figure I-2. Illustration of PPAR activation effect on metabolism related organ 
Metabolic responses that occur when PPAR is activated in organs involved in metabolism 





I-3. Histone deacetylases and HDAC3 
 
3.1 General information of Histone deacetylases 
Histone, as major components of chromatin, wraps DNA and regulates expression of DNA 
by its acetylation and deacetylation (Kruhlak et al., 2001). Levels of histone acetylation 
depend on the activities of histone acetylases (HATs) and Histone deacetylases (HDACs), 
which add or remove acetyl groups from protein substrates, respectively (Sun et al., 2003). 
HDACs are a class of enzymes that remove acetyl groups from amino acid on a histones 
(Sun et al., 2003). Generally, an increase in histone acetylation leads to remodeling of 
chromatin from condensed form to decondensed form, which subsequently causes 
transcriptional activation (Kazantsev and Thompson, 2008; Strahl and Allis, 2000). In other 
words, a decrease in histone acetylation causes chromatin structure to condense and result 
in transcriptional silencing. Therefore, HDACs play a role in suppressing gene expression 
in principle.  
The superfamily of HDACs is classified five main subtypes depending on sequence 
homology; class I, IIa and IIb, and IV, and the structurally distinct class III (Gregoretti et 
al., 2004). Class I, II and IV are considered "classical" HDACs whose have a zinc ion 
dependent active site, while Class III is a family of NAD+-dependent enzymes known as 
sirtuins (Thiagalingam et al., 2003). 
Class I HDACs consist of the ubiquitously expressed HDAC1, HDAC2 and HDAC3, and 
the muscle-specific expressed HDAC8. HDAC1 and HDAC2 are predominantly localized 
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in the nucleus, whereas HDAC3 shuttles between the nucleus and cytoplasm. HDAC1 and 
HDAC2 are almost identical and are components of stable transcriptional repressive 
complexes termed SIN3A, NuRD, CoReST and PRC2 complexes (Yang and Seto, 2003). 
These complexes are recruited to gene promoters by DNA binding proteins, which suggests 
gene specific rather than global transcriptional regulation (Wen et al., 2000). HDAC3 is 
found in distinct complexes such as the NCoR, SMRT complex (Yang et al., 2002), whereas 
no complex has been described for HDAC8 (Yang and Seto, 2008). 
Class IIa HDACs consist of HDAC4, HDAC5, HDAC7 and HDAC9 with distinct tissue 
specific patterns of expression, predominantly in muscle and heart (Martin et al., 2007). 
These HDACs have conserved binding sites for the transcription factor myocyte enhancer 
factor 2 (MEF2) and the chaperone protein 14-3-3, which fine-tune HDACs signal 
responsive (Butler and Bates, 2006). Following phosphorylation by kinases, such as 
calcium/calmodulin-dependent protein kinase (CaMK) and protein kinase D (PKD), these 
HDACs bind 14-3-3 and shuttle from the nucleus to the cytoplasm (McKinsey et al., 2000). 
Modulated phosphorylation of lass IIa HDACs provide a mechanism for connecting 
extracellular signals with transcription and play an important role in many tissues during 
development and disease. 
Class IIb HDACs consist of HDAC6 and HDAC10. HDAC6 is the main cytoplasmic 
deacetylase in mammalian cells and functions as deacetylation of a-tubulin and alters 
microtubule stability (Zhang et al., 2008). HDAC10 has been found in a complex with 
HDAC3, although the exact function of HDAC10 is not known (Fischer et al., 2002). 
16 
 
Class IV HDAC consist only of HDAC11. Expression of HDAC11 is enriched in the brain, 
heart, muscle, kidney and testis, but little is known about its function (Gao et al., 2002).  
 
3.2 Physiological functions of HDAC3 
HDAC3 is one of the Class I HDACs family. HDAC3 is present in a distinct complex that 
contains either NCOR or its homolog SMRT (Perissi et al., 2010). However, HDAC3 not 
only forms a complex with NCoR/SMRT but also requires interaction with the deacetylase 
activating domain (DAD) of NCOR/SMRT for its enzyme activity (Guenther et al., 2001). 
Inositol tetraphosphate molecule Ins(1,4,5,6)P4 (IP4) which embedded at the interface 
between HDAC3 and DAD stabilizes the interaction between HDAC3 and DAD (Watson 
et al., 2012). Interestingly, knockin mice with mutations in NCOR and SMRT DADs live 
to adulthood despite the undetectable deacetylase activity in the embryos. On the other hand, 
the global deletion of HDAC3 is embryonic lethal (You et al., 2013). This suggests HDAC3 
deacetylase function is not essential for survival. 
Deletion of HDAC3 in cardiomyocytes induced to an increase in ligand-induced lipid 
storage in the heart. In the heart, these genes that control fatty acid uptake and metabolism 
are under the control of the nuclear receptor PPARα, and the inhibition by loss of HDAC3 
leads to metabolic disorder observed in diabetic cardiomyopathy. Furthermore, loss of 
HDAC3 in the heart results in robust interstitial fibrosis, which is phenotypically 
independent of PPARα activity. Overexpresion of HDAC3 in the heart leads to increased 
thickness of the myocardium, which is due to increased cardiomyocyte hyperplasia without 
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hypertrophy. In conclusion, Hdac3 is a novel regulator of cardiac myocyte proliferation 
during cardiac development (Trivedi et al., 2008). 
Loss of HDAC3 in the liver impairs lipid and cholesterol homeostasis, leading to an 
accumulation of lipids and a decrease in glycogen storage. These changes are usually 
caused by inhibition of the gene program under the control of thyroid hormone receptors 
and nuclear hormone receptors such as PPAR, which control the major steps of lipid and 
cholesterol biosynthesis in the early postnatal liver (Knutson et al., 2008). Liver specific 
Hdac3 deficient mice have higher insulin sensitivity without any changes in insulin 
signaling or body weight compared to wild-type mice. Perilipin 2, which coats lipid droplets, 
is induced upon Hdac3 depletion and contributes to both hepatic steatosis and improved 
glucose tolerance. Hdac3 depletion reroutes metabolic precursors towards lipid synthesis 





I-4. Metabolic disorders 
 
4.1 Obesity 
Obesity is a medical condition that is caused by accumulating of excess body fat and 
negatively affect people’s health. The World Health Organization has listed obesity as one 
of the top ten global health problems in Western cultures; some consider it the most 
dangerous disease in the world today (Heymsfield and Wadden, 2017). There are various 
factors that induce obesity; increasing per capita food supplies and consumption, decreasing 
time spent in physical activities; increasing usage of medicines that have weight gain as a 
side effect; insufficient sleep. These factors cause the energy balance to collapse and cause 
chronic weight gain (Heymsfield and Wadden, 2017). 
Almost ten years ago, the cloning of the ob gene (encoding leptin) opened a new era of 
obesity research. Leptin is a fat-derived cytokine that is directly associated with body fat 
mass and transfers the energy state of the organism to the brain (Zhang et al., 1994). An 
abnormally leptin signaling is recognized as starvation by brain, leading to starvation and 
energy conservation even in the state of extreme obesity. The existence of this 
neuroendocrine system implies that excessive eating behavior is not just the will of the 
individual, but regulates by genes (Seeley and Woods, 2003). Another factor which relates 
with obesity, PPAR is a master regulator of the differentiation of adipocytes and their 
ability to function normally. PPAR is induced during adipocyte differentiation and forced 
expression of PPAR in non-adipogenic cells effectively converts to mature adipocytes 
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(Tontonoz et al., 1994). In conclusion, recent research indicates that the genetic changes are 
also important, although the living environmental factors are important factor to cause 
obesity. 
  
4.2 Hepatic steatosis  
Hepatic steatosis is one of the most prevalent metabolic disorders in the world, defining 
the clinical characteristics of non-alcoholic fatty liver disease (NAFLD) (Cohen et al., 2011). 
Hepatic steatosis is an abnormal accumulation of TGs in the cytoplasm of hepatocytes (Fig. 
I-3). Hepatic steatosis is a premorbid condition, which increases the vulnerability of liver 
to progress to steatohepatitis and to more advanced stages of liver disease (Brunt and 
Tiniakos, 2010). In contrast to healthy livers, up-regulation of PPAR expression is a 
common property of steatotic livers (Memon et al., 2000).  
Consistent with these findings, hepatic PPAR overexpression has been linked to 
exacerbated steatosis by activation of de novo lipogenesis and increased hepatic TG 
concentrations. Similarly, liver-specific knockout of PPAR in obese ob/ob mice reduces 
hepatic lipid accumulation and reduces the expression of many genes important for lipid 
metabolism (Gavrilova et al., 2003; Matsusue et al., 2003). Moreover, the administration of 
TZD shows increased lipid storage and improves hepatic steatosis in NAFLD patients by 
the primary insulin sensitizing effect on adipose tissue (Ratziu et al., 2008). In contrast, 
prolonged treatment of TZD in obese KKAy mice, which show elevated levels of PPAR in 
the liver, results that severe hepatic steatosis may be present and adversely affect 
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intrahepatic lipid metabolism in people with altered liver expression of PPAR (Bedoucha 
et al., 2001). 
Overall, these results indicate that the precise role of PPAR in hepatocytes and whether 
the expression level of PPAR is a causative element or a consequence of hepatic steatosis, 







Figure I-3. Illustration of the process of hepatic steatosis progression 
When obesity is induced by overeating or decline of physical activity, adipose mass is 
increased in WAT. Increased adipose mass leads to the production of fatty acids and inhibits 
the secretion of adiponectin. As a result, the de novo lipogenesis process in the liver 
becomes active, so that the production and accumulation of triglyceride are increased, 
























ROR is known to be involved in various biological processes as an ONR whose ligand 
is yet defined. In the meantime, the in vivo function of ROR was studied using natural 
spontaneous ROR mutant mice, Staggerer mice. However, use of Staggerer mice has 
provided a limitation to the study on the in vivo function of ROR due to the side effect 
from ataxia. 
To solve this problem, I generated ROR conditional knockout mice. Using these mice, I 
generated liver-specific Ror deficient mice, which could be used to study function of 
ROR in the liver. When liver-specific Ror deficient mice were given over-nutrient stress 
by feeding HFD, severe obesity and hepatic steatosis were induced in liver-specific Ror 
deficient mice compared to WT mice. Thus, I observed that the weight and adipocyte size 
of WAT were also increased. By demonstrating the increased expression of inflammatory 
genes in WAT and the decreased expression of thermogenesis gene in BAT, I confirmed that 
genetic changes were also induced in adipose tissue due to obesity. Histological analysis 
showed that accumulation of lipid droplets in the liver of liver-specific Ror deficient mice 
resulted in severe hepatic steatosis. Similar to adipose tissues, expression of genes involved 
in lipid synthesis and lipid sequestration was increased in the liver. Finally, the GTT and 
ITT experiments have confirmed that glucose tolerance and insulin sensitivity were also 
impaired. Together, I generated liver-specific Ror deficient mice and found that the 





Obesity is a medical condition in which the accumulation of fat is excessive. Thus, 
obesity is a high risk metabolic disorder, leading to various complications, including 
cardiovascular disease, hyperlipidemia, and type II diabetes (Despres and Lemieux, 2006; 
Heymsfield and Wadden, 2017). Ectopic accumulation of fat in various tissues activates 
numerous cellular stress and inflammatory signaling pathways, resulting in insulin 
resistance, pancreatic β cell dysfunction, and hepatic steatosis (Rutkowski et al., 2015). 
Hepatic steatosis is a typical NAFLD disease caused by the accumulation of liver fat. It is 
known that when hepatic steatosis exacerbates, it progresses to hepatitis, liver cirrhosis and 
liver cancer (Cohen et al., 2011). The liver is the central metabolic organ to regulate key 
aspects of glucose and lipid metabolism including gluconeogenesis, fatty acid β-oxidation, 
lipoprotein uptake and secretion, and lipogenesis (van den Berghe, 1991). Given that portal 
vein is a critical path to convey insulin signaling from pancreas during fed state, the hepatic 
glucose and lipid metabolism are directly under control of nutrient signaling. 
Dysregulation of hepatic lipid metabolism results in the development of hepatic 
steatosis, contributing to the chronic insulin resistance and steatotic hepatitis (Browning 
and Horton, 2004). The hepatic metabolic pathways are governed by highly dynamic 
transcriptional networks of orphan nuclear receptors (ONRs), including PPARs, farnesoid 
X receptor (FXR), and liver X receptor (LXR) (Chawla et al., 2001a). Many ONRs are 
expressed in tissues involved in metabolism, such as skeletal muscle, adipose tissue, and 
liver (Bookout et al., 2006), and play critical roles in the regulation of metabolism (Pearen 
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and Muscat, 2012). Genetic studies have shown that many ONRs regulate nutrient 
metabolism and physiology of obesity and type II diabetes (Li et al., 2009). Given that 
numerous synthesized ligands for ONRs are used for developing putative drugs for human 
metabolic diseases (Katz et al., 2009), ONRs are emerging as therapeutic targets for the 
treatment of metabolic diseases. 
Previously, ROR, a member of ONRs, possesses tumor suppressive function by 
transrepressing canonical Wnt/-catenin signaling leading to inhibition of colon cancer 
growth and by increasing p53 stability upon DNA damage response (Kim et al., 2011; Lee 
et al., 2010). However above all, ROR is known to regulate cerebellum development 
(Vogel et al., 2000). The Staggerer mice, natural Ror spontaneous mutant mice, display 
ataxia and severe cerebellar atrophy (Doulazmi et al., 1999). Moreover, ROR functions to 
regulate circadian rhythm as a key regulator of the cyclic expression of BMAL1 together 
with REV-ERB (Guillaumond et al., 2005). The ROR/REV-ERB feedback loop 
controls the circadian expression pattern of BMAL1, indicating that ROR plays a key role 
in the core circadian clock (Sato et al., 2004). In addition, Staggerer mice show lower 
expression levels of genes involved in lipid metabolism, including apolipoprotein A-1 
(apoA1) and apolipoprotein C-III (apoCIII) (Mamontova et al., 1998; Vu-Dac et al., 1997). 
Besides, the expression of several genes involved in the main and alternative pathway of 
triglyceride synthesis, including Gpam, Agpat9 and Mogat1 were significantly diminished 
in Staggerer mice liver. Thus, Staggerer mice exhibit less body weight gain compared with 
wild-type (WT) mice despite their higher food consumption (Lau et al., 2008). When 
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Staggerer mice get old, exhibit a reduced body fat index. Adipocytes are smaller in brown 
and white adipose tissue of Staggerer mice than WT mice and the level of triglycerides is 
lower in liver of Staggerer mice than WT mice (Kang et al., 2011). However, when ROR 
is overexpressed in liver by adenovirus infection system, lipid accumulation, hepatic 
steatosis, and expression of genes involved in lipogenesis are reduced (Kim et al., 2012). 
The reason for this contradiction is that Staggerer mice have huge cerebellar defects, it is 
still possible that physiological changes observed in Staggerer mice are indirect effects. 
Thus, the physiological roles of ROR to control transcriptional networks to modulate 
lipogenesis and gluconeogenesis still remain unclear.  
In this study, I report that ROR plays a key role to control hepatic lipid metabolism 
to protect against diet-induced obesity and hepatic steatosis, using liver-specific Ror 
deficient mouse model. HFD-fed liver-specific Ror deficient mice (RORLKO mice) show 
severe metabolic defects, including hepatic steatosis, obesity, and insulin resistance, 




II-3. Results  
 
Generation of conditional Ror deficient mice  
  To determine the physiological roles of ROR in the liver, I generated Ror floxed mice 
(hereafter named RORf/f) by gene targeting in ES cells (Fig. II-1A). To generate mice with 
a floxed ROR allele, FRT-flanked puromycin cassette containing a loxP sequence was 
inserted at the front of ROR exon 4 and the single loxP site was inserted at the back of 
ROR exon 5. Then, this targeted vector was electroporated to E14Tg2A ES cells. 
Surviving clones of ES cells after puromycin selection were expanded and analyzed by 
Southern blot to confirm for recombinant ES clones. After BamHI digestion, the bands 
representing WT and mutant alleles are 9.0 and 6.8 kb, respectively (Fig. II-1B). ES cells 
were injected into the C57BL/6 blastocyst to produce chimeras, then male chimeras were 
mated with C57BL/6 female mice to select for germline transmission. After that, I crossed 
Ror floxed mice with Albumin-Cre (Alb-Cre) mice to selectively create liver-specific 





Figure II-1. Generation of conditional Ror deficient mouse 
(A) Schematic representation of the Ror gene-targeting strategy to generate a hepatic-
specific Ror deficient mouse, including a map of the ROR exon 4 and 5 allele (yellow 
box) and the targeting vector with loxP sites (red arrowhead), FRT sites (blue box), and 
puromycin selection gene (Pr, green box). Bg: BglII, RI: EcoRI, Bh: BamHI, Kp: KpnI, Sp: 
SpeI. (B) Southern blot analysis to screen correctly targeted Ror +/puro ES cell clones. 
For BamHI digestion, the bands representing WT and mutant alleles were 9.0 kb and 6.8 
kb, respectively. (C) PCR analyses with genomic DNA extracted from tail of WT, RORf/+, 
Alb; RORf/+, RORf/f, and Alb; RORf/f mice are shown. PCR were performed to amplify 




ROR has no effect the development of the liver 
To ensure that the liver-specific ROR knockout mice were made correctly, I checked the 
mRNA and protein levels of hepatic ROR. The mRNA and protein levels of endogenous 
hepatic ROR were remarkably depleted in RORLKO mice compared with littermate 
controls, RORf/f in both liver and primary hepatocyte (Fig. II-2A-D). Above all, it is well 
known that ROR is involved in the development of the cerebellar. Therefore, I examined 
whether there is any defect in the liver developmental process of RORLKO mice as ROR 
can affect the liver development process. H&E staining of 12 weeks old RORf/f and 
RORLKO mice liver showed no significant defect in the liver developmental process (Fig. 
II-2E). Through this, further research is proceeded based on the fact that the liver 





Figure II-2. Identification of ROR deficiency and the liver developmental process in 
RORLKO mice 
(A and B) mRNA expression level of ROR in liver extract (A) and primary hepatocyte (B) 
from RORf/f and RORLKO mice. Expression was normalized to 18s rRNA expression. 
Data expressed as mean ± S.E.M. (C and D) Protein expression level of ROR in liver 
extract (C) and primary hepatocyte (D). (E) Representative image of liver from 12 weeks 
old RORf/f and RORLKO mice stained with hematoxylin and eosin. Magnification is 
shown in the figure. 
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Metabolic changes are not observed in liver specific ROR knockout mice at normal 
conditions  
In previous experiments, I observed that ROR did not have a significant effect in the 
liver developmental process; after that I examined whether metabolic changes occurred in 
RORLKO mice. Body composition analysis revealed that RORLKO mice exhibited similar 
fat/lean mass, free body fluid and adipocytes size with those of RORf/f when RORf/f and 
RORLKO mice fed CD during 10 weeks from 8 weeks old (Fig. II-3A, B). Then, I examined 
metabolic changes in RORf/f and RORLKO mice fed CD using the metabolic cage system. 
As a result, no obvious changes were observed between CD-fed RORf/f and RORLKO 
mice. O2 consumption, CO2 production, respiratory exchange ratio, energy expenditure 
and food consumption were very similar in CD-fed RORf/f and RORLKO mice (Fig. II-
3C-G). These results suggest that RORLKO mice do not show metabolic changes under 






Figure II-3. Metabolic characterization of RORf/f and RORLKO mice fed CD 
(A) Body composition analysis of RORf/f and RORLKO mice fed CD for 10 weeks 
(n=6/group). (B) Representative image of eWAT from RORf/f and RORLKO mice fed CD 
for 10 weeks stained with hematoxylin and eosin. Scale bar, 100 μm. (C-G) Metabolic cage 
studies were performed in RORf/f and RORLKO mice fed CD for 10 weeks (n=6 
mice/group). O2 consumption (VO2) (C), CO2 production (VCO2) (D), respiratory 
exchange ratio (RER) (E), energy expenditure (EE) (F) and food consumption (G) were 




High fat diet induces extraordinary obesity in liver-specific Ror deficient mice 
To determine ROR affects metabolism in the liver, I decided to observe metabolic 
changes in RORf/f and RORLKO mice under metabolic stress conditions like feeding HFD. 
First, I measured the growth rate of RORLKO mice and observed that they attained body 
weights similar to RORf/f mice fed CD during 10 weeks from 8weeks old (Fig. II-4A). 
However, when placed on a HFD, RORLKO mice exhibited a significant increase of the 
weight gain (20 vs. 25 gram) compared with their RORf/f littermates, resulting in 
extraordinary obesity (Fig. II-4A). Body composition analysis and macroscopic view 
revealed that RORLKO mice had more fat mass (Fig. II-4B, C). All white and brown fat 
depots from RORLKO mice were significantly increased in mass relative to RORf/f (Fig. 
II-4D). During obesity, adipose tissue expands by hyperplastic and/or hypertrophic growth. 
The cross-sectional area of adipocytes in visceral fat tissue was markedly increased in 






Figure II-4. Liver-specific Ror deficient mice are susceptible to diet-induced obesity 
(A) Body weight change in RORf/f and RORLKO mice fed CD or HFD for 10 weeks (n=9-
12/group). Data expressed as mean ± S.E.M. Statistical analysis was performed using 
Student’s unpaired t-test. *p<0.05, RORf/f vs. RORLKO, HFD. (B) Body composition 
analysis of RORf/f and RORLKO mice fed HFD for 10 weeks (n=6/group). Data expressed 
as mean ± S.E.M. Statistical analysis was performed using Student’s unpaired t-test. 
**p<0.01, ***p<0.001. (C) Macroscopic views of body size in RORf/f and RORLKO mice. 
(D) Adipose tissue weight of RORf/f and RORLKO mice fed HFD for 10 weeks (n=6-
7/group). Data expressed as mean ± S.E.M. Statistical analysis was performed using 
Student’s unpaired t-test. *p<0.05, ***p<0.001, NS=Non-Significant. (E) Representative 
image of eWAT from RORf/f and RORLKO mice fed HFD for 10 weeks stained with 




Expression of pro-inflammatory genes in white adipose tissue and thermogenesis 
genes in brown adipose tissue is abnormal in HFD-fed liver-specific Rordeficient 
mice 
 Through H&E staining of eWAT, I confirmed that macrophage infiltrated into eWAT of 
RORLKO mice and eWAT of RORLKO mice formed crown-like shape. This is a 
histological evidence that inflammation is increased in adipocytes by obesity. In addition, 
through previous studies, several proinflammatory factors are produced in adipose tissue 
with increasing obesity. Compared with that of lean mice, adipose tissue in obese mice 
shows higher expression of pro-inflammatory genes (Samad et al., 1998). Therefore, I 
examined expression level of pro-inflammatory genes in eWAT. Consequentially, 
induction of pro-inflammatory genes, including Mcp1, Ifnγ, and F4/80 in visceral fat depot 
were potentiated in RORLKO mice (Fig. II-5A).  
The activities of brown adipose tissue reduce metabolic disorder, including obesity. 
Expression of genes that induce thermogenesis in brown adipose tissue is reduced when 
mice are obese (Harms and Seale, 2013). Consistent with a significant weight gain in HFD-
fed RORLKO mice, gene expression analysis revealed reduction of Pgc1, as well as a 
number of genes involved in thermogenesis, mitochondrial biogenesis, and fatty acid 
oxidation in brown adipose tissue of RORLKO mice compared with that of RORf/f 





Figure II-5. Expression of inflammatory cytokine genes in eWAT and thermogenesis 
genes in BAT is impaired in HFD-fed RORLKO mice 
(A) Expression levels of inflammatory cytokine genes in eWAT extract from RORf/f and 
RORLKO mice fed HFD for 10 weeks (n=4-5/group) as determined by qRT-PCR. 
Expression was normalized to L32 expression. (B) Expression levels of thermogenesis 
genes in BAT extract from RORf/f and RORLKO mice fed HFD for 10 weeks (n=4-
5/group) as determined by qRT-PCR. Expression was normalized to L32 expression. Data 
expressed as mean ± S.E.M. Statistical analysis was performed using Student’s 




Whole-body metabolic rate and production of bile acid reduce in HFD-fed RORLKO 
mice 
  The observation that energy expenditure in brown fat has been impaired in HFD-fed 
RORLKO mice led us to examine whether they have global metabolic defects. Although no 
obvious defects were observed in CD-fed mice (Fig. II-3C-G), HFD-fed RORLKO mice 
were found to produce far less CO2, consume less O2 and expend less energy than RORf/f 
littermates, indicating that oxidative phosphorylation is impaired by the hepatic deletion of 
ROR (Fig. II-6A-C). However, RER and food consumption were no difference between 
RORf/f and RORLKO mice (Fig. II-6D, E).  
Previously, bile acids have been reported to increase energy expenditure by promoting 
intracellular thyroid hormone activation in brown adipose tissue (Watanabe et al., 2006) 
(Fig. II-7). I observed that expression of key genes involved in hepatic bile acid synthesis 
was remarkably reduced in HFD-fed RORLKO mice (Fig. II-8A). Consistently, serum bile 
acid pool sizes in HFD-fed RORLKO mice were markedly less than RORf/f littermates 
(Fig. II-8B), implicating that reduction of bile acid synthesis and bile acid pool size led to 






Figure II-6. Whole-body metabolic rate is depressed in HFD-fed RORLKO mice 
(A-E) Metabolic cage studies were performed in RORf/f and RORLKO mice fed HFD for 
10 weeks (n=5-6 mice/group). O2 consumption (VO2) (A), CO2 production (VCO2) (B), 
respiratory exchange ratio (RER) (C), energy expenditure (EE) (D) and food consumption 
(E) were represented. Data expressed as mean ± S.E.M. Statistical analysis was performed 





Figure II-7. Illustration of increased energy expenditure of BAT by bile acid 
The synthesis of bile acid from cholesterol is increased by the Cyp genes in the liver. The 
bile acid is secreted from the liver and binds to TGR5 of BAT. Activated TGR5 increases 
the expression of Dio2 that converts inactive thyroxine (T4) into active 3,5,3′-





Figure II-8. Expression of hepatic bile acid related genes and serum bile acid pool 
size are decreased in RORLKO mice fed HFD 
(A) Expression levels of bile acid related genes in liver extract from RORf/f and RORLKO 
mice fed HFD for 10 weeks (n=7/group) as determined by qRT-PCR. Expression was 
normalized to 36B4 expression. (B) Bile acid level of serums that were collected from 
RORf/f and RORLKO mice fed HFD for 10 weeks (n=6/group). BW, body weight. Data 






ROR protects against HFD-induced hepatic steatosis 
Obesity is largely associated with hepatic steatosis in humans as well as in rodents. 
Consistent with obese phenotype in RORLKO mice, large lipid vesicles with increased 
amounts were observed in the hepatocytes of HFD-fed RORLKO mice (Fig. II-9A), 
whereas no difference was observed in CD-fed RORf/f and RORLKO mice because CD-
fed RORf/f and RORLKO mice had no significant phenotypically difference (Fig. II-9B). 
Macroscopically, liver from HFD-fed RORLKO mice was markedly enlarged and paler 
compared with HFD-fed RORf/f liver (Fig. II-9C). Consistently, HFD-fed RORLKO mice 
exhibited a remarkable increase of liver weight compared with HFD-fed RORf/f mice (Fig. 
II-9D). In accordance with hematoxylin and eosin staining, oil red O staining, and hepatic 
triglyceride (TG) analysis showed a dramatic increase in lipid level in the HFD-fed 
RORLKO liver compared with the HFD-fed RORf/f liver, whereas no difference was 
observed in CD-fed RORf/f and RORLKO mice (Fig. II-9E-G). While hepatic gene 
expression profiles were similar among CD-fed genotypes (Fig. II-10A), hepatic gene 
expression profiles of lipogenesis, gluconeogenesis, and lipid sequestration in the HFD-fed 
RORLKO were largely increased, indicating that ROR protects against HFD-induced 











Figure II-9. Liver-specific Ror deficient mice are susceptible to diet-induced hepatic 
steatosis  
(A-G) RORf/f and RORLKO mice were fed with HFD or CD for 10 weeks. (A and B) 
Representative liver histological section images of HFD-fed RORf/f and RORLKO mice 
(A) or CD-fed RORf/f and RORLKO mice (B) stained with hematoxylin and eosin. Scale 
bar, 100 μm. (C) Macroscopic view of livers from HFD-fed RORf/f and RORLKO mice. 
(D) Liver weights of HFD-fed RORf/f and RORLKO mice (n=10-11/group). Data 
expressed as mean ± S.E.M. Statistical analysis was performed using Student’s unpaired t-
test. **p<0.01. (E) Triglyceride content of livers from HFD-fed RORf/f and RORLKO 
mice (n=8/group). Data expressed as mean ± S.E.M. Statistical analysis was performed 
using Student’s unpaired t-test. *p<0.05. (F and G) Representative liver histological section 
images of HFD-fed RORf/f and RORLKO mice (F) or CD-fed RORf/f and RORLKO mice 





Figure II-10. Expression of hepatic lipid metabolism related genes is increased in the 
liver of RORLKO mice fed HFD but is no obvious change in the liver of RORLKO 
mice fed CD 
(A and B) RORf/f and RORLKO mice were fed with HFD or CD for 10 weeks. 
Hepatic gene expression profile involved in metabolism from the livers of CD-fed 
RORf/f and RORLKO mice (n=5/group) (A) or HFD-fed RORf/f and RORLKO 
mice (n=4/group) (B) as determined by qRT-PCR. Expression was normalized to 
36B4 expression. Data expressed as mean ± S.E.M. Statistical analysis was 




Hepatic steatosis impairs insulin sensitivity in liver-specific Ror deficient mice 
 Obesity and hepatic steatosis often predispose rodents and humans to impaired glucose 
homeostasis and insulin resistance (Kahn and Flier, 2000; Moller and Kaufman, 2005). 
Hepatic deficiency of ROR resulted in elevated fasting insulin levels in RORLKO mice 
(Fig. II-11A). As elevated fasting insulin level is an indication of insulin resistance, 
RORLKO mice predisposed to severe insulin resistance than RORf/f mice. Consistent with 
elevated fasting insulin level, an investigation of insulin signaling pathways confirmed 
reduction of phosphorylated AKT, indicating that insulin signaling was impaired in HFD-
fed RORLKO mice (Fig. II-11B). As insulin signaling was impaired in the liver, I performed 
glucose tolerance tests (GTTs) and insulin tolerance tests (ITTs) to determine if glucose 
homeostasis was impaired in HFD-fed RORLKO mice. Glucose intolerance and insulin 
resistance were observed in HFD-fed RORLKO mice, although CD-fed RORLKO mice 
exhibited little or no difference in glucose homeostasis compared with CD-fed RORf/f 
mice (Fig. II-11C, D). Altogether, my data strongly demonstrate that hepatic ROR is 





Figure II-11. Insulin sensitivity is impaired in liver-specific Ror deficient mice 
(A) Fasting insulin levels in HFD-fed RORf/f and RORLKO mice (n=6-7/group). Data 
expressed as mean ± SEM. Statistical analysis was performed using Student’s unpaired t-
test. *p<0.05. (B) Immunoblot analysis was performed from liver extracts of HFD-fed 
RORf/f and RORLKO mice. (C and D) Glucose tolerance test (GTT) (C) and insulin 
tolerance test (ITT) (D) on RORf/f and RORLKO mice fed on CD or HFD for 10 weeks. 
(n=4-9/group). Data expressed as mean ± S.E.M. Statistical analysis was performed using 





 In this study, I generated and used ROR conditional knockout mice instead of natural 
ROR spontaneous mutant mice, Staggerer mice. Until this time, Staggerer mouse was 
inevitable for in vivo study of ROR. In Staggerer mice, physical behavior is restricted by 
its ataxia and cerebellar atrophy, so the physiological side-effect was very great that it was 
difficult to study about in vivo function of RORDoulazmi et al. However, this 
study allowed to study in vivo function of ROR in various organs using ROR conditional 
knockout mice.  
ROR is known to participate in the regulation of various metabolic processes including 
lipid metabolism. In particular, studies using Staggerer mice confirmed that the expression 
of genes involved in TG production and lipogenesis is decreased (Kang et al., 2011; Lau et 
al., 2008). As a result, Staggerer mice are less obese and progression of hepatic steatosis is 
slower, and the size of adipocyte is also smaller than that of wild type mice. However, when 
ROR was overexpressed in the liver, it was found that the progress of hepatic steatosis 
was rather slow. Thus, the role of ROR in the regulation of metabolic processes in the 
liver was controversial due to limitations of studies using Staggerer mice.  
In this study, liver-specific Ror deficient mice were generated and available for research. 
When liver-specific Ror deficient mice were fed the HFD, it was surprisingly found that 
size of adipocytes and weight gain were increased unlike Staggerer mice. Various metabolic 
rates of liver-specific Ror deficient mice also decreased due to obesity. The expression of 
inflammatory genes in WAT and thermogenesis genes in BAT were decreased in liver-
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specific Ror deficient mice. In addition, hepatic steatosis was more severe than wild type 
mice and TG accumulation in the liver was also increased. The expression of genes involved 
in lipogenesis and lipid sequestration in the liver was increased. Finally, I confirmed that 
glucose tolerance and insulin sensitivity in liver-specific Ror deficient mice were impaired 
by GTT and ITT experiments. All of these phenomena did not occur when mice fed CD, 
but only when mice fed HFD. Previous studies have shown that RORplays a role in 
mitigating stress under environmental stress. In other words, in the liver, ROR plays a 





II-5. Materials and Methods 
 
Generation of conditional Ror deficient mice and animal care 
To generate mice with a floxed ROR allele, a 16.5-kb region used to construct the targeting 
vector was first subcloned from a BAC clone (bMQ-293I20, Source BioScience) into a 
pBluescript phagemid system. The FRT-flanked puromycin cassette containing a loxP 
sequence was inserted at the front of exon 4 and the single loxP site was inserted at the back 
of exon 5. The target region was ~15.2 kb which included exon 4 and 5. Twenty micrograms 
of the targeting vector was linearized by SalI and then electroporated to E14Tg2A ES cells. 
Surviving clones after puromycin selection were expanded and analyzed by Southern blot 
to confirm recombinant ES clones. After BamHI digestion, the bands representing WT and 
mutant alleles are 9.0 and 6.8 kb, respectively. Targeted ES cells were selected for 
microinjection into C57BL/6 blastocysts to generate chimeras. The male chimeras were 
bred with C57BL/6 female mice to select for germline transmission. To remove the 
puromycin selection cassette, targeted heterozygous F1 was crossed with Flp deleter strain 
(FLPeR mice, The Jackson Laboratory strain 003946). The mice were backcrossed to 
C57BL/6 then crossed with Alb-Cre mice (The Jackson Laboratory strain 003574) to 
generate liver-specific Ror deficient mice. Male RORf/f and RORLKO mice at 8 weeks 
of age were fed a CD or a 60% kcal fat HFD (Research diet, D12492) during 10 weeks. The 
sample sizes for all animal studies were announced in each figure legend. Mice were housed 
in a specific pathogen-free AAALAC-accredited facility under controlled conditions of 
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temperature (25°C) and light (12 hr light:12 hr dark, lights switched on at 7:00 AM). Food 
and water were available ad libitum. All mice used in these experiments were backcrossed 
to C57BL/6 at least seven generations. The primers used in PCR analysis for genotyping 
floxed alleles are: forward 5′-GCTTGTGGGTTTCTCCTACA-3′ and reverse 5′-
GCAGCAAGTGTTGTGTCCCA-3′. This study was reviewed and approved by the 
Institutional Animal Care and Use Committee (IACUC) of National Cancer Center 
Research Institute.  
 
Body composition 




Oxygen consumption (VO2), carbon dioxide production (VCO2), respiratory exchange 
ratios (RER), energy expenditure (EE) and food consumption were measured using an 
indirect calorimetry system PHENOMASTER (TSE System). Mice in each chamber were 
maintained at a constant environmental temperature of 22 °C. 
 
Isolation and culture of primary mouse hepatocytes 
Mouse primary hepatocytes were isolated from the liver of 8 weeks old male RORf/f and 
RORLKO mice or WT and PPARα null mice. The hepatocyte isolation method used was 
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described previously (Kang et al., 2016). Dissociation into individual hepatocytes was 
performed in Dulbecco’s modified Eagles’ medium (DMEM) (Welgene) containing 10% 
heat-inactivated FBS, 1% antibiotics, 20mM HEPES, 100 nM insulin, 1 nM dexamethasone. 
For each hepatocyte preparation, cell viability was estimated by the exclusion of trypan 
blue. 
 
Total bile acid (TBA) measurement 
The quantitative determination of TBA of mice serum that was collected after centrifugation 
of mice blood was measured using the total bile acids assay kit (DZ042A-K, Diazyme 
Laboratories), according to the manufacturer’s instructions.  
 
Histology 
When mice were sacrificed by CO2 exposure, livers and WATs were rapidly fixed in 10% 
formalin (Sigma) at 4°C overnight. After fixation, tissues were sequentially dehydrated in 
ethanol with increasing concentrations ranging from 50 % to 100 %. Dehydrated specimens 
were subsequently infiltrated with 100 % xylene and embedded in paraffin wax. For 
hematoxylin and eosin (H&E) staining, tissues were sectioned at 5 μm thickness, 
deparaffinized, rehydrated and stained with hematoxylin for 3 min followed by 
counterstaining with eosin for 1 min. For Oil red O staining, fresh samples of liver 
embedded in OCT tissue freezing medium (Sakura Finetek). 0.5 % Oil red O solution was 
prepared by dissolving 0.5 g Oil red O powder (Sigma) in 100 ml propylene glycol (sigma). 
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Fresh frozen specimens were cryosectioned at 8 μm thickness and air dried. Then fix in ice 
cold 10 % formalin for 10 min, air dried again, and rinsed with distilled water. Sections 
were placed in 100 % propylene glycol for 5 min and stained with pre-warmed 0.5 % Oil 
red O solution in propylene glycol for 15 min in 60 °C oven. Then sections were rinsed 
with distilled water and followed by counterstaining with hematoxylin. Images were 
acquired using digital microscopes (Leica DMD108, Leica microsystems) equipped with 
10 x and 20 x objective lenses. 
 
Quantitative real-time RT-PCR 
Total RNAs were extracted using Trizol (Invitrogen) and reverse transcription was 
performed from 2.5 g of total RNAs using the M-MLV cDNA Synthesis kit (Enzynomics). 
The abundance of mRNA was detected by a CFX384 TouchTM Real-Time PCR Detection 
System (Bio-Rad) with SYBR Green (Enzynomics). The quantity of mRNA was calculated 
using Ct method and normalized by using primers indicated in each figure legend. All 
reactions were performed as triplicates. Primers used for analysis are as follows: 
mRor Forward(Fwd) :5′-CAATGCCACCTACTCCTGTCC-3′ and Reverse (Rev): 5′-
GCCAGGCATTTCTGCAGC-3′; m18s rRNA Fwd: 5′-CCGCAGCTAGGAATAATGGA-
AT-3′ and Rev: 5′-GCCAGGCATTTCTGCAGC-3′; mMcp1 Fwd: 5′-GGCTCAGCCAGA-
TGCAGTTAAC-3′ and Rev: 5′-AGCCTACTCATTGGGATCATCTTG-3′; mIfn Fwd: 5′-
ATGAACGCTACACACTGCATC-3′ and Rev: 5′-CCATCCTTTTGCCAGTTCCTC-3′; 
mIl-1 Fwd: 5′-CGGCACACCCACCCTG-3′ and Rev: 5′-AAACCGCTTTTCCATCTTC-
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TTCT-3′; mIl-18 Fwd: 5′-CAGGCCTGACATCTTCTGCAA-3’ and Rev: 5′-TCTGACAT-
GGCAGCCATTGT-3′; mTgf Fwd: 5′-CTTCAATACGTCAGACATTCGGG-3′ and Rev: 
5′-GTAACGCCAGGAATTGTTGCTA-3′; mF4/80 Fwd: 5′-TGACAACCAGACGGCTT-
GTG-3′ and Rev: 5′-GCAGGCGAGGAAAAGATAGTGT-3′; mDio2 Fwd; 5′-AATTATG-
CCTCGGAGAAGACCG-3′ and Rev: 5′-GGCAGTTGCCTAGTGAAAGGT-3′; mAcadm 
Fwd: 5′-AGGGTTTAGTTTTGAGTTGACGG-3′ and Rev: 5′-CCCCGCTTTTGTCATAT-
TCCG-3′; mPgc1 Fwd: 5′-TATGGAGTGACATAGAGTGTGCT-3′ and Rev: 5′-CCACT-
TCAATCCACCCAGAAAG-3′; mEsrrFwd: 5′-AGGTGGACCCTTTGCCTTTC-3′ and 
Rev: 5′-GGCATGGCGTACAGCTTCT-3′; mUcp1 Fwd: 5′-AGGCTTCCAGTACCATTA-
GGT-3′ and Rev: 5′-CTGAGTGAGGCAAAGCTGATTT-3′; mAox Fwd: 5′-TAACTTCCT-
CACTCGAAGCCA-3′ and Rev: 5′-AGTTCCATGACCCATCTCTGTC-3′; mL32 Fwd:5′-
GAAACTGGCGGAAACCCA-3′ and Rev: 5′-GGATCTGGCCCTTGAACCTT-3′; 
mCyp7a1 Fwd: 5′-TCATTGCTTCAGGGCTCCTG-3′ and Rev: 5′-TGGGCATCT-
CAAGCAAACAC-3′; mCyp8b1 Fwd: 5′-CCTCTGGACAAGGGTTTTGTG-3′ and Rev: 
5′-GCACCGTGAAGACATCCCC-3′; mCyp27a1 Fwd: 5′-CCAGGCACAGGAGAGTAC-
G-3′ and Rev: 5′-GGGCAAGTGCAGCACATAG-3′; mGcK Fwd: 5′-CTGGATGACAGA-
GCCAGGATG-3′ and Rev: 5′-AGTTGGTTCCTCCCAGGTCT-3′; mPepck Fwd: 5′-
AAAAGCCTTTGGTCAACAAC-3′ and Rev: 5′-AAACTTCATCCAGGCAATGT-3′; 
mPpar Fwd: 5′-TCGCTGATGCACTGCCTATG-3′ and Rev: 5′-GAGAGGTCCACAGA-
GCTGATT-3'; mSrebp1c Fwd: 5′-GAAGCTGTCGGGGTAGCGTCT-3′ and Rev: 5′-
CTCTCAGGAGAGTTGGCACCTG-3′; mAcc Fwd: 5′-GGACAGACTGATCGCAGAG-
AAAG-3′ and Rev: 5′-TGGAGAGCCCCACACACA-3′; mFasn Fwd: 5′-GCTGCGGAA-
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ACTTCAGGAAAT-3′ and Rev: 5′-AGAGACGTGTCACTCCTGGACTT-3′; mScd1 Fwd: 
5′-TTCTTGCGATACACTCTGGTGC-3′ and Rev: 5′-CGGGATTGAATGTTCTTGTCG-
T-3′; mAcaca Fwd: 5′-ATGGGCGGAATGGTCTCTTTC-3′ and Rev: 5′-TGGGGACCTT-
GTCTTCATCAT-3′; mAcacb Fwd: 5′-CGCTCACCAACAGTAAGGTGG-3′ and Rev: 5′-
GCTTGGCAGGGAGTTCCTC-3′; mDgat2 Fwd: 5′-GCGCTACTTCCGAGACTACTT-3′ 
and Rev: 5′-GGGCCTTATGCCAGGAAACT-3′; mChrebp Fwd: 5′-CATTGCCAACATA-
AGCATCTTC-3′ and Rev: 5′-GTCCGATATCTCCGACACACTC-3′; mCidec Fwd: 5′-
ATGGACTACGCCATGAAGTCT-3′ and Rev: 5′-CGGTGCTAACACGACAGGG-3′; 
mPlin2 Fwd: 5′-GACCTTGTGTCCTCCGCTTAT-3′ and Rev: 5′-CAACCGCAATTTGT-
GGCTC-3′; mG0S2 Fwd: 5′-TAGTGAAGCTATACGTTCTGGGC-3′ and Rev: 5′-GTCTC-
AACTAGGCCGAGCA-3′. 
 
Intraperitoneal glucose or insulin tolerance tests 
For GTTs, 2 g of glucose per kg of mice body weight was injected i.p. to overnight fasted 
mice. For ITTs, 0.75 U of insulin (Humulin R, Eli Lilly) per kg of mice body weight was 
injected i.p. to 6 hr fasted mice. Mice blood was drawn at indicated time intervals from the 




Commercially available antibodies were used: anti-ROR (sc-28612; 1:1,000 dilution for 
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IB analysis) and anti-AKT (sc-8312; 1:1,000 dilution for IB analysis) from Santa Cruz 
Biotechnology; anti--actin (A5441; 1:5,000 dilution for IB analysis) from Sigma; anti-
phospho-AKT(Ser473) (#4051S, 1:1,000 dilution for IB analysis) from Cell Signaling.  
 
Statistical analysis  
The statistical analysis of different groups is realized using the Student’s unpaired t-test 
or one-way ANOVA followed by Tukey post hoc test or two-way ANOVA. SPSS 













ROR requires HDAC3 to regulate PPAR signaling to 
maintain hepatic lipid homeostasis                   









 To determine how ROR inhibits diet-induced obesity through molecular mechanisms, I 
analyzed total transcriptome of the liver through mRNA sequencing data of the liver. As a 
result, ROR inhibited the PPAR signaling. I have demonstrated that ROR suppresses 
PPAR signal by observing the increase of expression of several PPAR target genes 
involved in various lipid metabolism including lipid synthesis in liver-specific ROR 
deficient mice.  
ROR binds to DNA without binding to PPAR and inhibits the transcriptional activity of 
PPAR. I found that ROR competes with PPAR on PPRE through that the AGGTCA 
sequence of the DR1 motif of PPRE is the same as the core motif sequence of RORE, which 
inhibits the transcriptional activity of PPAR. At this time, it was shown that ROR binds 
to HDAC3 rather than to PPAR to inhibit the transcriptional activity of PPAR. 
Since ROR is involved in the metabolism process via the inhibition of PPAR signaling, 
inhibition of the PPAR signaling, independent of ROR, will restore the phenotype of 
liver-specific ROR deficient mice. Therefore, I administrated GW9662, a synthetic 
antagonist of PPAR, to liver-specific Ror deficient mice. As a result, liver-specific Ror 
deficient mice were found to be inhibited in the progression of obesity and hepatic steatosis. 





PPAR is mainly expressed in WAT and BAT, where it is a major regulation organ of 
adipogenesis. Therefore PPAR is known for a regulator of lipid metabolism and insulin 
sensitivity (Tontonoz and Spiegelman, 2008). PPAR is activated by various ligands. After 
ligand binding to PPAR, PPAR heterodimerizes with retinoid X receptor  (RXR) and 
activates genes involved in lipid metabolism and insulin sensitivity (Chawla et al., 2001b). 
Whereas PPAR is mainly expressed in WAT and BAT, PPAR is expressed in liver by a 
high-fat diet (Medina-Gomez et al., 2007). In addition, liver-specific deletion of PPAR in 
mice established its role as a pro-steatotic factor in the development of NAFLD (Way et al., 
2001). Contrary, the activation of PPAR by TZD promotes the release of free fatty acids 
in the liver, while increasing fat mass and consequently improving insulin sensitivity 
(Mayerson et al., 2002; Musso et al., 2012). Therefore, it is unclear what precise function 
of PPAR is in hepatic lipid metabolism. 
 The mode of action of PPAR in liver was suggested to promote insulin sensitivity but 
with concomitant development of fatty liver. PPAR1 is overexpressed in PPAR knockout 
mice using adenovirus. These PPAR1 overexpressed PPAR knockout mice showed 
PPAR1 induced adipocyte specific gene expression patterns in the liver (Yu et al., 2003). 
Therefore, elevated PPAR activity can lead to the development of hepatic steatosis. In 
addition, hepatic adenoviral overexpression of PPAR2 in lean mice increased liver 
triglyceride content and induced hypertension (Uno et al., 2006). Then, in studies using A-
ZIP/F-1 (AZIP) mice models in which PPAR was reduced in the liver, showed severe 
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lipoatrophic diabetes, attenuation of hepatic steatosis but compromised triglyceride 
clearance (Gavrilova et al., 2003). Moreover, when PPAR agonist, rosiglitazone, was 
administrated to AZIP mice, an improvement of glucose metabolism was observed. 
Hepatocyte specific PPAR deficient mice protected mice due to lipid accumulation in a 
high fat diet feeding, thus further suggesting its role in the development of hepatic steatosis. 
They also showed that the PPAR in Kupffer cells might not be involved in the development 
of hepatic steatosis (Moran-Salvador et al., 2011). In addition, a mouse model of 
dyslipidemia showed that hepatic PPAR2 upregulation induced hepatic de novo 
lipogenesis. These mice are obese, insulin resistant and have hepatic steatosis (Zhang et al., 
2006). Taken together, these studies strongly implicate PPAR in the development of 
hepatic steatosis. 
HDAC3 is the Class I HDACs, it is a member of corepressor complex NCOR and SMRT 
(Perissi et al., 2010). Depletion of HDAC3 in liver impairs lipid and cholesterol 
homeostasis, so lipid accumulation is increased and glycogen storage is decreased. 
Moreover, liver specific Hdac3 deficient mice have improved insulin sensitivity, but insulin 
signaling pathway or body weight have no changes compared with wild-type mice (Knutson 
et al., 2008). HDAC3 depletion reroutes metabolic precursors towards lipid synthesis and 
storage within lipid droplets and away from hepatic glucose production (Sun et al., 2012).  
Here, genome-wide transcriptome analysis reveals that PPAR signaling is remarkably 
elevated in RORLKO mice. ROR specifically recruits HDAC3 to the PPAR target 
promoters to suppress PPAR transcriptional activity. Finally, PPAR antagonism by using 
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PPAR antagonist GW9662, largely ameliorates body weight gain and hepatic steatosis in 
HFD-fed RORLKO mice, indicating that dysregulated PPAR signaling is a critical 
metabolic cue, leading to metabolic defects in HFD-fed RORLKO mice. Together, my data 
demonstrate that ROR controls PPAR signaling to protect against hepatic metabolic 





HFD-fed RORLKO mice exhibit enhanced PPAR transcriptional activity 
To explore molecular mechanism by which hepatic deletion of ROR induces obesity and 
insulin resistance, I performed mRNA-sequencing analysis of liver tissues obtained from 
HFD-fed RORf/f, HFD-fed RORLKO, CD-fed RORf/f, and CD-fed RORLKO mice 
(Table III-1). Using the resulting mRNA expression profiles, I first identified 343 
differentially expressed genes (DEGs; P< 0.05) between HFD-fed RORLKO and HFD-fed 
RORf/f mice (RORLKO/RORf/fHFD in Fig. III-1A) and also 395 DEGs between CD-fed 
RORLKO and CD-fed RORf/f mice (RORLKO/RORf/fCD in Fig. III-1A). Moreover, I 
further compared log2-fold-changes of the DEGs in the two comparisons above 
((RORLKO/RORf/fHFD)/(RORLKO/RORf/fCD) in Fig. III-1A) and identified the genes 
specifically affected by ROR under HFD condition as the DEGs showing significant (P< 
0.05) differences in the log2-fold-changes. I categorized these DEGs into 8 groups (Groups 
1-8) based on differential expression patterns in the three comparisons above. My data 
above showed that I only found significant weight gain of RORLKO mice under HFD 
condition. Of Groups 1-8, thus, I first focused on Groups 1-4 showing significant changes 
under HFD condition (Fig. III-1A).  
To understand cellular processes represented by Groups 1-4, I performed enrichment 
analysis of gene ontology biological processes (GOBPs) and Kyoto Encyclopedia of Genes 
and Genomes (KEGG) pathways for the genes in Groups 1-4 using DAVID software 
(Huang da et al., 2009a, b) (Table III-2). Group 1 is mainly involved in the processes related 
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to PPAR and adipocytokine signaling pathways and fatty acid/retinol metabolism (Fig. III-
1B and Table III-2, 3). Group 4 is mainly involved in the processes related to circadian 
rhythm (Table III-2, 3). Since Group 1 is highly associated with the weight gain of HFD-
fed RORLKO, I next examined which transcription factors (TFs) account for up-regulation 
of the genes in Group 1 under HFD condition. By performing TF enrichment analysis of 
the genes in Group 1 using ChEA2 software (Kou et al., 2013), PPAR turned out to be the 
most enriched TF in Group 1 (Fig. III-1C and Table III-4). Quantitative RT-PCR analysis 
confirmed that the genes in Group 1 including PPAR target genes are largely elevated in 
HFD-fed RORLKO mice (Fig. III-1D), indicating that PPAR transcriptional activity is 












Figure III-1. Transcriptome analysis of hepatic gene expression profile in RORLKO 
mice 
(A) Up- and down-regulated genes in RORLKO compared to RORf/f mice. These genes 
were categorized into 4 groups of the up- (Groups 1, 2) and down-regulated genes (Groups 
3, 4) in HFD-fed RORLKO. Besides Groups 1-4, remain genes were also categorized into 
4 groups of the up- (Groups 5, 6) and down-regulated genes (Groups 7, 8) in CD-fed 
RORLKO. Groups 1, 2 (or Groups 3, 4) were further divided by the specificity of the ROR 
effect under HFD condition. Log2-fold changes in the following comparisons were 
displayed: RORLKO/RORf/fHFD, RORLKO/RORf/fCD, and 
(RORLKO/RORf/fHFD)/(RORLKO/RORf/fCD). Hierarchical clustering of the DEGs in 
Groups 1-8 (Euclidian distance as a dissimilarity measure and average linkage) were used 
to display the log2-fold changes. (B) KEGG pathways enrichment analysis for the genes in 
Group 1. The bars represent the enrichment scores, -log10 (P value). (C) TF enrichment 
analysis for the genes in Group 1 using ChEA2 software. Top 3 TFs are shown. The bars 
represent the enrichment scores, -log10 (P value). (D) Expression levels of group 1 genes 
(up-regulated genes in RORLKO mice fed HFD compared with RORf/f mice) in liver 
extract from RORf/f and RORLKO mice fed CD or HFD for 10 weeks (n=5-9/group) as 
determined by qRT-PCR. Expression was normalized to 36B4 expression. Data expressed 
as mean ± S.E.M. Statistical analysis was performed using two-way ANOVA. *p<0.05, 





Table III-1. Summary of the alignment results for mRNA-sequencing data 
Among the raw reads generated from Illumina Hiseq-2500, the reads after trimming low 
quality and adapter sequences were used for the alignment. On average, each 98.5 % of the 
reads (Mapped reads and Mapping rate) were aligned to a reference mouse genome 
(GRCm38). Of the mapped reads, 92.1 % (Unique mapping rate) of the mapped reads were 
aligned to unique location (Uniquely mapped reads) in the genome. Exom Coverage 













Table III-2. GOBPs and KEGG pathways represented by the genes in Groups 1-4 
The GOBPs and KEGG pathways represented by the genes in Groups 1-8 are shown. For 
each GOBP or KEGG pathway term, the count of the genes involved in the term and the 
enrichment P-values for the term are shown. The GOBPs and KEGG pathways with P-









Table III-3. List of genes affected by depletion of ROR 
List of up- (Group 1) and down- (Group 4) regulation of the genes affected by ROR 
depletion in the following three comparisons are shown: 1) CD-fed RORLKO versus CD-
fed RORf/f (KO/WTCD), 2) HFD-fed RORLKO versus HFD-fed RORf/f (KO/WTHFD), and 




Table III-4. Key transcription factors significantly regulating the genes in Group 1 
TFs significantly enriched by the genes in Group 1 (P-value < 0.01) are shown. For each 




ROR regulates PPAR transcriptional network but does not affect 
PPARtranscriptional network in the mice liver 
PPAR is a transcriptional factor that conducts a key role in hepatic lipid metabolism and 
shares similar response elements with PPAR on the target promoters (Dreyer et al., 1992; 
Lee et al., 2014). To determine whether ROR also mediates PPAR transcriptional 
network in the liver, I examined the expression of well-known hepatic PPAR target genes, 
including Acox1 and Fgf21. The hepatic gene expressions of Acox1 and Fgf21 in HFD-fed 
RORLKO mice were similar to those of HFD-fed RORf/f mice, suggesting that ROR 
deficiency would not further enhance hepatic PPAR transcriptional network (Fig. III-2A) 
under HFD condition. I next examined the expression of PPAR target genes in the 
physiological setting of PPAR activation. It has been widely accepted that PPAR is 
activated under conditions of energy deprivation (Kersten et al., 1999). The induction of 
PPAR target genes in RORLKO mice was quite similar to that of RORf/f mice (Fig. III-
2B). Chromatin immunoprecipitation (ChIP) assay clearly revealed little or no difference 
of PPAR recruitment to PPAR-response element (PPRE) on the promoters of PPAR 
target genes (Fig. III-2C). Recently, PPAR has been reported to bind autophagic gene 
promoters to coordinate autophagy in response to nutrient deprivation (Lee et al., 2014). I 
observed that the induction of autophagic genes including LC3a and Sesn2 of RORLKO 
mice were similar to those of RORf/f mice (Fig. III-2D). Taken together, these data indicate 
that ROR mainly controls PPAR transcriptional network rather than PPAR in the liver 









Figure III-2. PPAR and ROR do not affect their roles in the mice liver with each 
other 
(A) Expression levels of PPAR target genes in liver from RORf/f and RORLKO mice fed 
CD or HFD for 10 weeks (n=7-9/group) as determined by qRT-PCR. Expression was 
normalized to 36B4 expression. Data expressed as mean ± S.E.M. Statistical analysis was 
performed using Student’s unpaired t-test. NS=Non-Significant. (B-D) 24 h fasted and 24 
h refed after 24 h fasting RORf/f and RORLKO mice were euthanized to collect livers. (B) 
Expression levels of PPAR target genes in liver from RORf/f and RORLKO mice fasted 
or refed (n=3/group) as determined by qRT-PCR. Expression was normalized to 36B4 
expression. (C) ChIP assays were performed on the Acox1 and Fgf21 promoters in liver 
extract form RORf/f and RORLKO mice fasted or refed (n=3/group). Promoter occupancy 
by PPAR and GFP was analyzed. (D) Expression levels of autophagy-related PPAR 
target genes in liver from RORf/f and RORLKO mice fasted or refed (n=3/group) as 
determined by qRT-PCR. Expression was normalized to 36B4 expression. Data expressed 
as mean ± S.E.M. Statistical analysis was performed using two-way ANOVA. *p<0.05, 





ROR inhibits the transcriptional activity of PPAR regardless of the various co-
activator of PPAR 
Since PGC1 is a well-known coactivator for PPAR (Puigserver and Spiegelman, 2003), 
I examined whether introduction of ROR inhibits PPAR/PGC1-dependent 
transcriptional activation using PPRE-containing luciferase reporter. Expression of PGC1 
dramatically increased PPAR transcriptional activity, and increased expression of ROR 
progressively attenuated the PPAR/PGC1-dependent transcriptional activation (Fig. III-
3A). In addition, I examined whether ROR inhibits NCOA1 and NCOA2-mediated 
PPARtranscriptional activation. NCOA1 and NCOA2, as p160 family members, are also 
coactivators for PPAR (Hong et al., 1996). Consistently, ROR significantly reduced 






Figure III-3. ROR inhibits the transcriptional activity of PPAR 
(A-C) Effect of overexpression of ROR on PPRE-luciferase reporter activity with 
coactivator PGC1 (A) or NCOA1 (B) or NCOA2 (C). Data expressed as mean ± S.E.M. 
Statistical analysis was performed using one-way ANOVA followed by Tukey’s post hoc 




ROR does not bind to PPAR, but directly binds to DNA and to inhibit 
transcriptional activity of PPAR 
To evaluate the role of ROR in attenuation of the PPAR-dependent transcriptional 
activation, I treated Hep3B cells with rosiglitazone, a PPAR synthetic agonist, and then 
measured PPRE-luciferase activity. Knockdown of ROR markedly enhanced PPRE-
luciferase activity, indicating that ROR functions to repress PPAR transcriptional activity 
(Fig. III-4A). To determine if DNA binding domain (DBD) of ROR is required for 
inhibiting PPAR transcriptional activation, I introduced DBD-deleted ROR mutant 
(ROR DBD). I observed that ROR WT markedly suppressed PPAR transcriptional 
activation, whereas the ROR-mediated repression was remarkably relieved by 
introduction of ROR DBD (Fig. III-4B). As ROR failed to interact with PPAR (Fig. 
III-4C), my data proposed that ROR suppresses PPAR transcriptional activation through 
DBD and possibly competes with PPAR for the binding to PPRE. Consistently, the 
recruitment of RORwas markedly reduced in PPRE-deleted synthetic promoter region 





Figure III-4. ROR recruits to PPRE and inhibits transcription activity of PPAR, 
but does not interact with PPAR 
(A) Effect of knockdown of ROR on PPRE-luciferase reporter activity. Cells were treated 
with DMSO (vehicle), rosiglitazone (20 μM) for 24 hr. Data expressed as mean ± SEM. 
Statistical analysis was performed using one-way ANOVA followed by Tukey’s post hoc 
analysis. *p<0.05, **p<0.01, compared to shNS group. (B) Effect of ROR DBD mutant 
on PPRE-luciferase reporter activity. Data expressed as mean ± S.E.M. Statistical analysis 
was performed using one-way ANOVA followed by Tukey’s post hoc analysis. ***p<0.001. 
(C) Co-immunoprecipitation assay was performed to detect the interaction between ROR 
and PPAR of HEK293T cells. (D) WT PPRE promoter and PPRE deleted mutant promoter 
containing luciferase reporter plasmid and Flag/Flag-ROR/Flag-PPAR plasmid were 
transfected into Hep3B cells. ChIP assays were performed on promoter region of reporter 
plasmid in Hep3B cells. Promoter occupancy by Flag was analyzed. Data expressed as 




ROR represses PPAR transcriptional activity via interacting with HDAC3 
Since histone acetylation promotes transcriptional activation, I next examined whether 
ROR interacts with specific histone deacetylases for the repression of PPAR 
transcriptional activity. Co-immunoprecipitation assay revealed that ROR specifically 
interacts with HDAC3 (Fig. III-5A, B). To determine if HDAC3 is required for ROR-
mediated repression of PPAR transcriptional activity, I further examined repressive 
function of HDAC3 for PPRE-luciferase activity in the presence or absence of ROR. 
Intriguingly, knockdown of ROR relieved the HDAC3-dependent repressive function 
indicating that HDAC3 exerted repressive function on PPARtranscriptional activity in the 
presence of ROR (Fig. III-5C). Consistently, knockdown of HDAC3 largely reversed 
ROR-mediated repression of PPAR transcriptional activity (Fig. III-5D-F). These results 










Figure III-5. ROR interacts with HDAC3 to repress PPAR transcriptional activity 
(A) Co-immunoprecipitation assay was performed to detect the interaction between ROR 
and HDACs of HEK293T cells. (B) Co-immunoprecipitation assay was performed to detect 
the interaction between ROR and HDAC3 of HEK293T cells. (C) Effect of ROR on 
PPRE-luciferase reporter activity by HDAC3 overexpression. Data expressed as mean ± 
S.E.M. Statistical analysis was performed using one-way ANOVA followed by Tukey’s post 
hoc analysis. *p<0.05, **p<0.01, compared to PPAR/PGC1 group. (D-F) Effect of 
knockdown of HDAC3 with coactivator PGC1 (D) or NCOA1 (E) or NCOA2 (F) on 
PPRE-luciferase reporter activity. Data expressed as mean ± S.E.M. Statistical analysis was 





ROR recruits to the PPAR target gene promoters with HDAC3 in liver of mice fed 
HFD without involvement of PPAR 
PPRE consists of a Direct Repeat (DR) sequence of (A/G)GGTCA spaced by one 
nucleotide, whereas consensus ROR response element (RORE) consists of core motif 
(A/G)GGTCA preceded by a 6-bp A/T-rich sequence. Thus, given that RORE and PPRE 
share core motif, I hypothesized that ROR directly binds the PPRE of PPAR target 
promoters for transcriptional repression. To examine whether ROR and HDAC3 are co-
recruited to the PPAR target promoters for the repression, I performed ChIP assay with 
anti-ROR, PPAR, PPAR, RNA polymerase II (Pol II), acetylated H3 (H3Ac), and 
HDAC3 antibodies from the mouse liver extracts of CD or HFD-fed RORf/f and RORLKO 
mice. ChIP assays revealed that ROR and HDAC3 were co-recruited to the Cd36, Scd1 
and Plin2 promoters in the liver of HFD-fed RORf/f mice (Fig. III-6), although no changes 
were observed with CD-fed RORf/f mice (Fig. III-7). In the absence of ROR, PPAR 
recruitment was markedly increased, whereas HDAC3 recruitment was largely diminished 
along with elevated acetylated H3 levels on the Cd36, Scd1 and Plin2 promoters in the liver 
of HFD-fed RORLKO mice (Fig. III-6). Unlike PPAR, PPAR recruitment was barely 







Figure III-6. ROR recruits to the PPAR target gene promoters with HDAC3 in liver 
of mice fed HFD 
(A-C) ChIP assays were performed on the Cd36 (A), Scd1 (B) and Plin2 (C) promoters in 
liver extract form RORf/f and RORLKO mice fed HFD for 10 weeks (n=3/group). 
Promoter occupancy by ROR, PPAR, HDAC3, H3Ac, Pol II, PPAR and GFP was 
analyzed. Schematic of promoter region was represented with gene name. Red bar depicts 
locations of PPRE. Data expressed as mean ± S.E.M. Statistical analysis was performed 




Figure III-7. The recruitment of PPAR to the PPAR target gene promoters is similar 
between RORf/f and RORLKO mice fed CD unlike mice fed HFD 
(A-C) ChIP assays were performed on the Cd36 (A), Scd1 (B) and Plin2 (C) promoters in 
liver extract form RORf/f and RORLKO mice fed CD for 10 weeks (n=3/group). Promoter 
occupancy by ROR, PPAR, PGC1, HDAC3, H3Ac, Pol II, PPAR and GFP was 
analyzed. Schematic of promoter region was represented in previous figure. Data expressed 
as mean ± S.E.M. Statistical analysis was performed using Student’s unpaired t-test. 




Figure III-8. PPAR recruitment is almost absent in the target gene promoter of 
PPAR 
ChIP assays were performed on the Cd36, Scd1, Acox1 and Fgf21 promoters in liver extract 
form RORf/f and RORLKO mice fed HFD for 10 weeks (n=3/group). Promoter occupancy 
by PPARwas analyzed. Data expressed as mean ± S.E.M. Statistical analysis was 





PPAR and ROR/HDAC3 dynamically regulate PPAR target gene expression  
Next, I determined if both ROR and HDAC3 are recruited to the PPRE in response to 
PPAR agonist in Hep3B cells (Fig. III-9A). Treatment of rosiglitazone largely induced the 
expression of PPAR target genes (Fig. III-9B). Interestingly, 8 hr washout after 
rosiglitazone treatment dramatically reduced PPAR target gene expressions (Fig. III-9A, 
B). Consistent with gene expressions, treatment of rosiglitazone increased recruitment of 
PPAR, PGC1 and Pol II with elevated histone H3 acetylation level on PPAR target 
promoters as well as induction of PPAR target genes (Fig. III-10). Strikingly, further 
increased recruitment of ROR to PPRE was observed along with enhanced HDAC3 
recruitment in the setting of washout of rosiglitazone for 8 hours (Fig. III-10). Increased 
recruitment of ROR and HDAC3 substantially diminished PGC1 and Pol II recruitment 





Figure III-9. Expression of PPAR target genes changes in response to Rosi.+washout 
experimental conditions 
(A) Schematic representation of experimental design. (B) Expression levels of PPAR 
target genes in the absence or presence of ROR in Hep3B cells with or without 
Rosiglitazone (20 μM) treatment for 24 hr and washout 8 hr as determined by qRT-PCR. 
Expression was normalized to HPRT expression. Data expressed as mean ± S.E.M. 
Statistical analysis was performed using one-way ANOVA followed by Tukey’s post hoc 







Figure III-10. ChIP assay in response to Rosi.+washout experimental conditions 
(A-D) ChIP assays were performed on the CD36 (A), SCD (B) and PLIN2 (C) promoters 
and GAPDH negative region (D) in Hep3B cells with or without Rosiglitazone (20 μM) 
treatment for 24 hr and washout 8 hr. Promoter occupancy of ROR, PPAR, HDAC3, Pol 
II, PGC1, H3Ac and GFP was analyzed. Schematic of promoter region was represented 
with gene name. Red bar depicts locations of PPRE. Data expressed as mean ± S.E.M. 
Statistical analysis was performed using one-way ANOVA followed by Tukey’s post hoc 






The recruitment of ROR to PPAR target genes promoter increases when PPAR 
signal is reduced  
Next, I further determined whether PPAR antagonist GW9662 also resulted in the 
increased recruitment of ROR and HDAC3 to the PPAR target promoters. Consistent 
with the results from 8 hr washout, GW9662 treatment significantly reduced the expression 
levels of PPAR target genes (Fig. III-11A). ChIP assay revealed that recruitment of ROR 
and HDAC3 to the PPAR target promoters were markedly increased, while PPAR and Pol 










Figure III-11. The recruitment of ROR to PPAR target genes promoter increases 
when PPAR signal is reduced and it is opposite to PPAR recruitment 
(A) Expression levels of PPAR target genes in Hep3B cells with or without Rosiglitazone 
(20 μM) treatment for 24 hr and after treated GW9662 24 hr as determined by qRT-PCR. 
Expression was normalized to HPRT expression. Data expressed as mean ± S.E.M. (B-D) 
ChIP assays were performed on the CD36 (B), SCD (C) and PLIN2 (D) promoters in Hep3B 
cells with or without Rosiglitazone (20 μM) treatment for 24 hr and after treated GW9662 
24 hr. Promoter occupancy of ROR, PPAR, HDAC3, Pol II, PGC1, H3Ac and GFP was 
analyzed. Schematic of promoter region was represented in previous figure. Data expressed 
as mean ± SEM. Data expressed as mean ± S.E.M. Statistical analysis was performed using 





ROR is required to recruit HDAC3 to PPAR target genes promoter 
To address HDAC3 recruitment to PPAR target gene promoters requires ROR, I first 
examined the PPAR target gene induction in the presence or absence of ROR. The 
induction of PPAR target genes by rosiglitazone was further enhanced by ROR siRNA, 
indicating that ROR is a critical transcriptional repressor for PPAR target gene expression 
(Fig. III-12A). ROR knockdown largely increased the recruitment of PPAR for 
transcriptional activation with increased levels of H3 acetylation to the PPAR target gene 
promoters (Fig. III-12B, C). While remarkably increased by rosiglitazone washout, the 
HDAC3 recruitment was substantially reduced by ROR knockdown even with setting of 
rosiglitazone washout (Fig. III-12B, C). Taken together, these data clearly indicate that 













Figure III-12. ROR is required to recruit HDAC3 to PPARγ target genes promoter 
(A) Expression levels of PPAR target genes and ROR in the absence or presence of 
ROR in Hep3B cells with or without Rosiglitazone (20 μM) treatment for 24 hr and 
washout 8 hr as determined by qRT-PCR. Expression was normalized to HPRT expression. 
Data expressed as mean ± S.E.M. Statistical analysis was performed using Student’s 
unpaired t-test. *p<0.05, **p<0.01, ***p<0.001, NS=Non-Significant. (B-C) ChIP assays 
were performed in the absence or presence of ROR on SCD (B) or PLIN2 (C) promoters 
in Hep3B cells with or without Rosiglitazone (20 μM) treatment for 24 hr and washout 8 
hr. Promoter occupancy of ROR, PPAR, HDAC3, Pol II, PGC1, H3Ac and GFP was 
analyzed. Data expressed as mean ± S.E.M. Statistical analysis was performed using 





Recruitment of ROR and PPAR to the PPAR target gene promoters are mutually 
exclusive 
 To determine if ROR competes with PPARfor the binding to the PPAR target 
promoters, I transiently knocked down PPAR in Hep3B cells. To mimic HFD feeding 
conditions in vitro, I treated cells with free fatty acid (FFA) and examined expression of 
PPAR target genes. I observed that FFA treatment markedly increased PPAR target gene 
expressions in both WT and Ppar-null mouse primary hepatocytes, indicating that PPAR 
failed to influence on PPAR transcriptional network in the setting of HFD (Fig. III-13A). 
Next, I tested PPAR target gene expressions in the presence of PPAR siRNA or HDAC3 
siRNA. While repressed by PPAR siRNA, expression of PPAR target genes was largely 
enhanced by HDAC3 siRNA in response to FFA treatment (Fig. III-13B). Consistent with 
gene expression, increased PPAR recruitment by FFA was substantially diminished by 
PPAR siRNA (Fig. III-14A, B). Interestingly, recruitment of ROR was dramatically 
increased to the PPAR target gene promoters, and HDAC3 recruitment was accompanied 






Figure III-13. PPAR fails to influence on PPAR transcriptional network but 
HDAC3 affects PPAR transcriptional network 
(A) Expression levels of PPAR target genes in primary hepatocyte from WT and PPAR-
/- mice with or without free fatty acid (FFA: Oleic acid 200 μM and Palmitic acid 100 μM) 
treatment for 36 hr as determined by qRT-PCR. Expression was normalized to 36B4 
expression. Data expressed as mean ± S.E.M. Statistical analysis was performed using two-
way ANOVA. *p<0.05, **p<0.01, ***p<0.001, NS=Non-Significant. (B) Expression levels 
of PPAR target genes in the absence or presence of PPAR/HDAC3 in Hep3B cells with 
or without fatty acid (FFA: Oleic acid 200 μM and Palmitic acid 100 μM) treatment for 24 
hr as determined by qRT-PCR. Expression was normalized to HPRT expression. Data 
expressed as mean ± S.E.M. Statistical analysis was performed using Student’s unpaired t-






Figure III-14. Recruitment of ROR and PPAR to the PPAR target gene promoters 
are mutually exclusive  
(A-B) ChIP assays were performed in the absence or presence of PPARon the CD36 (A) 
and SCD (B) promoters in Hep3B cells with or without free fatty acid (FFA: Oleic acid 200 
μM and Palmitic acid 100 μM) treatment for 24 hr. Promoter occupancy of PPAR, ROR, 
HDAC3, Pol II and GFP was analyzed. Data expressed as mean ± S.E.M. S Statistical 




RORand HDAC3 compete with PPAR for the binding to the PPAR target gene 
promoter 
  Furthermore, Re-ChIP assay clearly indicated that PPAR and ROR are able to bind to 
the same genomic region and their recruitments to promoter of target genes are mutually 
exclusive (Fig. III-15). These data strongly indicate that ROR and HDAC3 compete with 
PPAR for the binding to the target gene promoters for regulation of gene expressions with 
opposite transcriptional outputs. Altogether, my data demonstrate that ROR functions as 
a corepressor along with HDAC3 and is co-recruited to the PPAR target promoters for the 





Figure III-15. ROR and HDAC3 compete with PPAR for the binding to the target 
gene promoter 
Re-ChIP assays were performed in the absence or presence of ROR on PLIN2 promoters 
in Hep3B cells with or without Rosiglitazone (20 μM) treatment for 24 hr and after treated 
GW9662 24 hr to determine whether ROR and PPAR are assembled on the same 
promoter. Data expressed as mean ± S.E.M. Statistical analysis was performed using one-




RORis required to recruit HDAC3 and competes with PPAR for the binding to the 
PPAR target gene promoters 
 To determine whether ROR recruitment is accompanied by the presence of HDAC3, I 
examined recruitment of ROR to the PPAR target gene promoters in the presence of 
HDAC3 siRNA. While little or no difference of the recruitment of ROR and PPAR was 
observed, Pol II recruitment to the PPAR target gene promoters was markedly increased 
by HDAC3 knockdown (Fig. III-16A, B), indicating that the presence of HDAC3 affected 
the recruitment of RNA polymerase II to the PPAR target gene promoters. Taken together, 
these data indicate that both ROR and HDAC3 serve as transcriptional corepressors on 





Figure III-16. The presence of HDAC3 affected the recruitment of RNA polymerase 
II to the PPAR target gene promoters  
(A-B) ChIP assays were performed in the absence or presence of HDAC3on the CD36 (A) 
and SCD (B) promoters in Hep3B cells with or without free fatty acid (FFA: Oleic acid 200 
μM and Palmitic acid 100 μM) treatment for 24 hr. Promoter occupancy of PPAR, ROR, 
HDAC3, Pol II and GFP was analyzed. Data expressed as mean ± S.E.M. S Statistical 




PPAR antagonism restores metabolic homeostasis in HFD-fed RORLKO mice 
 Since ROR turned out to play a key role to repress PPAR transcriptional activity in vitro 
and in vivo, I next examined if inhibition of PPAR transcriptional activities restores 
impaired metabolic homeostasis. For this, PPAR antagonist GW9662 were treated to 
RORf/f and RORLKO mice for 5 weeks with HFD. Intriguingly, the body weight gain of 
both RORf/f and RORLKO mice were markedly reduced by GW9662 treatment compared 
with vehicle-treated control mice (Fig. III-17A). The reduction of body weight gain by 
GW9662 in RORLKO mice was much greater, leading to similar body weight to GW9662-
treated RORf/f mice, indicating that inhibition of PPAR activity remarkably reduces body 
weight gain in RORLKO mice (Fig. III-17A). Similar to reduced body weight gain, tissue 
weights of the liver and eWAT were markedly reduced by GW9662 treatment in both 
RORf/f and RORLKO mice (Fig. III-17B, C). Consistently, cross-sectional area of 
adipocytes was significantly reduced by GW9662 treatment (Fig. III-17D). In accordance 
with body weight reduction, PPAR antagonism markedly reduced hepatic steatosis in both 
RORf/f and RORLKO mice (Fig. III-17E). Consistently, gene expression profile analysis 
exhibited that target gene expression levels involved in hepatic gluconeogenesis and 
lipogenesis are largely reduced by GW9662 treatment (Fig. III-17F, G). Together, I 
demonstrate that enhanced PPAR transcriptional activity by ROR deficiency is de-
activated by PPAR antagonism to restore metabolic homeostasis, including body weight 












Figure III-17. PPAR antagonism restores metabolic homeostasis in RORLKO mice  
(A-E) RORf/f and RORLKO mice were fed HFD with or without GW9662 for 5 weeks 
(n=4-5/group). (A) Body weight curves. Data expressed as mean ± SEM. Statistical analysis 
was performed using Student’s unpaired t-test. *p<0.05, RORf/f vs RORLKO, vehicle. (B 
and C) Liver (B) and eWAT (C) weight of RORf/f and RORLKO mice were fed HFD with 
or without GW9662 for 5 weeks. Data expressed as mean ± S.E.M. Statistical analysis was 
performed using two-way ANOVA. *p<0.05, **p<0.01. (D and E) Representative 
histological section images from eWAT (D) and liver (E) of RORf/f and RORLKO mice 
fed HFD with or without GW9662 for 5 weeks. Scale bar, 100 μm. (F and G) Expression 
levels of PPAR target genes (F) or gluconeogenesis/lipogenesis/lipid sequestration genes 
(G) in liver from RORf/f and RORLKO mice fed HFD with or without GW9662 for 5 
weeks as determined by qRT-PCR. Expression was normalized to 36B4 expression. Data 
expressed as mean ± S.E.M. Statistical analysis was performed using Student’s unpaired t-





Obesity is one of the most prominent metabolic disorders, and the danger of obesity has 
recently been emphasized. Obesity has been studied primarily as a result of living 
environmental factors such as overeating and the reduction of physical activities. However, 
recent studies have shown that obesity can also be caused by genetic factors. Therefore, 
identifying genetic phenomena that control obesity is emerging as a new way to treat 
various metabolic disorders including obesity (Heymsfield and Wadden, 2017).  
PPAR is known to play a role in regulating adipocyte differentiation and lipid storage as 
an important regulator of the adipogenesis genes in adipocytes (Tontonoz et al., 1994) 
However, the role of PPAR in the liver, an important organ that regulates metabolism as 
well as adipocytes, has not yet been established. Recent studies have shown that PPAR 
plays a role in promoting lipid accumulation in the liver. In ob/ob mice, deficiency of 
PPAR resulted in the improvement of hepatic steatosis (Gavrilova et al., 2003; Matsusue 
et al., 2003), and liver-specific Ppar deficient mice had decreased hepatic steatosis when 
fed HFD (Moran-Salvador et al., 2011). These results suggest that inhibition of PPAR 
plays a role in inhibiting the progression of hepatic steatosis through inducing inhibition of 
lipid accumulation in the liver.  
In this study, I found that liver-specific Ror deficient mice fed HFD induced more severe 
obesity and promoted hepatic steatosis. To investigate what kind genetic changes caused 
the physiological consequences, I examined the expression pattern of total genes through 
total mRNA sequencing using the liver. As a result, it was confirmed that the PPAR signal 
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was greatly increased by ROR deficiency. This means that ROR plays a role in 
suppressing the PPAR signaling pathway in the liver. Since PPAR plays a role in 
promoting lipid accumulation in the liver, ROR suppresses the lipid accumulation in the 
liver through inhibition of PPARsignal.  
PPRE has a DR1 motif, the DR1 motif consists of two repeats of the AGGTCA sequence 
(Kliewer et al., 1992). Since the AGGTCA sequence is identical to the sequence of the core 
motif of RORE, it can be expected that ROR can bind to PPRE. I confirmed ROR 
recruited to PPRE through ChIP assay. Moreover, ROR and PPARcompeted with each 
other on PPRE and that ROR suppressed the PPAR transcriptional activity. At this point, 
I found that ROR bound with HDAC3 as a corepressor, then recruited HDAC3 to the 
PPRE and suppressed the PPAR signaling pathway. HDAC3 is also known to inhibit lipid 
production and sequestration in the liver to inhibit hepatic steatosis. In this study, a role of 
HDAC3 in the liver is to suppress PPAR signaling pathway via ROR.  
Liver-specific Ror deficient mice have severe obesity and hepatic steatosis because 
PPAR signaling pathway is not suppressed by ROR deficiency. At this time, suppression 
of the PPAR signaling may be expected to alleviate the metabolic disorder. Therefore, I 
examined whether the PPAR antagonist, GW9662, was administered to liver-specific 
ROR deficient mice to reconstitute obese and hepatic steatosis phenotypes. Liver - 
specific Ror deficient mice treated with GW9662 showed obesity and hepatic steatosis 
are ameliorated, and decreased expression of genes involved in lipogenesis and lipid 
sequestration. These results confirm that ROR is an important regulator of fine-tuning the 
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diet-induced obesity by inhibiting the PPAR signaling pathway.  
Taken together, my data shows that ROR binds HDAC3 and competes with PPAR on 
PPRE to suppress PPAR signaling in response to over-nutrient cue. These results clearly 
demonstrate the role of ROR in the liver, suggesting that modulation of ROR activity is 






III-5. Materials and Methods 
 
Analysis of mRNA-sequencing data 
After removing adapter sequences (TrueSeq universal and index adapters), I used 
cutadapter software (Martin, 2011) to trim the reads that PHRED scores lower than 20. 
Remaining reads were aligned to the mouse reference genome (GRCm38) using TopHat 
aligner (Trapnell et al., 2009). After the alignment, I quantified the expression of genes as 
Fragments Per Kilobase of transcript per Million mapped reads (FPKM) for each gene using 
Cufflinks (Trapnell et al., 2010). To identify the DEGs, I first selected the ‘expressed’ genes 
as the ones with FPKM larger than 1 under at least one of the eight samples. For the 
expressed genes, log2(FPKM+1) values were normalized across eight samples using the 
quantile normalization method. To identify the DEGs, for each gene, I calculated a T-
statistic and log2-fold-change in the comparisons of RORLKO/RORf/fHFD and 
RORLKO/RORf/fCD. I then estimated empirical distributions of T-statistics and log2-fold-
changes for the null hypothesis by random permutation of the eight samples (1000 
permutations). Based on the distributions, for each gene, I computed adjusted P-values for 
the observed T-statistic and log2-fold-change and the combined these P-values with 
Stouffer’s method (Hwang et al., 2005). Finally, I identified the DEGs as the ones that have 
the combined P-value ≤ 0.05 and absolute log2-fold-change ≥ 0.439, which is a cutoff value 
(the 95th percentile of the empirical distribution for log2-fold-changes) for each comparison. 
I further identified ROR-dependent genes under HFD condition as the ones with 
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significant differences between the log2-fold-change in the two comparisons above 
(RORLKO/RORf/fHFD and RORLKO/RORf/fCD) larger than 0.439. 
 
Functional enrichment analysis and TF enrichment analysis 
For the genes in Groups 1-8, enrichment analysis of GOBPs and KEGG pathways were 
performed using a DAVID software (Huang da et al., 2009b). I selected the GOBPs and 
KEGG pathways with P-value<0.05 as the ones represented by the genes analyzed. For 
the genes in Group 1, TF enrichment analysis was performed using a ChEA2 software 
(Kou et al., 2013). Among the TF-target gene data, only mouse TF-target gene data were 
used for the enrichment analysis. I selected the TFs with P-value<0.01 as the ones 
significantly regulating the genes in Group 1. 
 
Luciferase reporter assay 
HEK293T cells and Hep3B cells were grown and transiently transfected by using 
Polyethylenimine (PEI) and turbofect (Thermo Scientific, R0531). For luciferase reporter 
assays, 1 x 105 cells were seeded in DMEM supplemented with 10 % FBS and 1 % 
antibiotics. Cells were transfected with PPRE-luciferase reporters and -galactosidase 
expression constructs along with several expression constructs were indicated in each 
figure. Using a luciferase assay system (Promega), the luciferase activity was measured 
with a luminometer (Berthold Technologies) after 48 hr of transfection. Transfection 
efficiency was normalized by -galactosidase expression. The results were obtained from 





HEK293T cells that transfected with Flag-HDACs and HA-ROR were cultured and 
lysed with lysis buffer (200 mM NaCl, 50 mM Tris-HCl, pH 8.0 and 0.5 % NP40). About 
20 mg of cell extracts was immunoprecipitated with each 1 μg of anti-Flag antibody 
overnight and then incubated with 35 μl (50 % slurry) of protein A/G agarose beads for 
1 h. The immunoprecipitated materials were washed with 500 μl of washing buffer 
(150 mM NaCl, 50 mM Tris-HCl, pH 8.0, and 0.5 % NP40) for four times and bound 
materials were eluted by boiling in 50 μl of sampling buffer (2 % -mercaptoethanol, 5 % 
glycerol, 1 % SDS and 60 mM Tris-HCl, pH 6.8) and subjected to immunoblot analysis. 
Protein samples were resolved by sodium dodecyl sulphate-polyacrylamide gel 
electrophoresis (SDS-PAGE) Images of the immunoblots were visualized and recorded 
using the LAS 4000-mini system (Fujifilm). 
 
Chromatin Immunoprecipitation (ChIP) and Re-ChIP assays 
The ChIP assays were conducted as described. Cells were crosslinked with 1 % 
formaldehyde for 10 min at room temperature. Mouse livers were harvested and quickly 
washed with PBS and crosslinked with 1 % formaldehyde for 10 min at room temperature, 
followed by quenching with 0.125 M glycine solution for 5 min. Then, cells or harvested 
mouse livers were washed with ice-cold PBS two times. Chromatin fragmentation was 
performed by sonication in ChIP lysis buffer (50 mM Tris-HCl [pH 8.1], 1% SDS, 10 
mM EDTA [pH 7.6], and protease inhibitor cocktail) with an average size of 
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approximately 500 bp. Proteins were immunoprecipitated in ChIP dilution buffer (1% 
Triton X-100, 2 mM EDTA, 150 mM NaCl, 20 mM Tris-HCl [pH 8.1], and protease 
inhibitor cocktail). Crosslinking was reversed overnight at 65 °C in elution buffer (1% 
SDS, 0.1 M NaHCO3), and DNA was purified with a QIAquick Gel Extraction Kit 
(QIAGEN). For the Re-ChIP assay, components were eluted from the first 
immunoprecipitation reaction by incubation with 10 mM DTT at 37°C for 30 min and 
diluted 1:50 with ChIP dilution buffer containing 20 mM Tris-HCl (pH 8.1), 150 mM 
NaCl, 2 mM EDTA, and 1% Triton X-100 followed by reimmunoprecipitation with the 
secondary antibody. Precipitated DNA was analyzed by quantitative PCR. For real-time 
quantitative PCR analysis, 2 μl from 60 μl DNA extractions was used. All reactions were 
performed in triplicates. Primers used for analysis are as follows; 
mCd36 PPRE Fwd: 5′-GTGTGCCTTTTGCATCTTGA-3′ and Rev: 5′-GGGGCACTA-
ACAGAAAACGA-3′; mScd1 PPRE Fwd: 5′-CTTTGTGTAGCCCTGGCTGT-3′ and 
Rev: 5′-TGAGGTTACCTGTGGTCACG-3′; mPlin2 PPRE Fwd: 5′-GCTGGGGATTA-
CAGACCAGA-3′ and Rev: 5′-TCTTGGGGTTTTGGAAAATG-3′; mAcox1 PPRE Fwd: 
5′-CGGAAACCAGAAGGGAATG-3′ and Rev: 5′-TAGCCAACGACAATGAACC-3′; 
mFgf21 PPRE Fwd: 5′-TTTCTCCTGTGTTGAATCCC-3′ and Rev: 5′-GTTCCTGCCA-
AGTGTGTC-3′; CD36 PPRE Fwd: 5′-AGGGGGTGTGGTTGCATATT-3′ and Rev: 5′-
TCTGGGTGATGGGAAAAATC-3′; SCD PPRE Fwd: 5′-GTGGTGTGGTGTCGGTG-
TC-3′ and Rev: 5′-AGCCGGGAATTTAAAGGCTA-3′; GAPDH negative region Fwd: 




GW9662 treated mice 
HFD-fed RORf/f and RORLKO male mice at 8 weeks of age were subjected to 
GW9662 at a dose of 0.35 mg/kg body weight/day in their drinking water for 5 weeks 
or to an equivalence volume of vehicle. The sample sizes for this study was announced 
in figure legend. 
 
Quantitative real-time RT-PCR 
Total RNAs were extracted using Trizol (Invitrogen) and reverse transcription was 
performed from 2.5 g of total RNAs using the M-MLV cDNA Synthesis kit 
(Enzynomics). The abundance of mRNA was detected by a CFX384 TouchTM Real-Time 
PCR Detection System (Bio-Rad) with SYBR Green (Enzynomics). The quantity of 
mRNA was calculated using Ct method and normalized by using primers indicated in 
each figure legend. All reactions were performed as triplicates. Primers used for analysis 
are as follows: 
CD36 Fwd: 5′-AAGCCAGGTATTGCAGTTCTTT-3′ and Rev: 5′-GCATTTGCTGATG-
TCTAGCACA-3′; SCD Fwd: 5′-GCCCCTCTACTTGGAAGACGA-3′ and Rev: 5′-AA-
GTGATCCCATACAGGGCTC-3′; PLIN2 Fwd: 5′-ATGGCATCCGTTGCAGTTGAT-3′ 
and Rev: 5′-GGACATGAGGTCATACGTGGAG-3′; ROR Fwd: 5′-CGGTGCGCAG-
ACAGAGCTAT-3′ and Rev: 5′-CCACAGATCTTGCATGGAATAATT-3′; HPRT Fwd: 






Commercially available antibodies were used: anti-ROR (sc-28612; 1:1,000 dilution for 
IB analysis, 5 g for ChIP assay), anti-PPAR (sc-9000x, 1 g for ChIP assay) and anti-
GFP (sc-9996 , 1 g for ChIP assay) from Santa Cruz Biotechnology; anti--actin (A5441; 
1:5,000 dilution for IB analysis) and anti-FLAG (F3165, Sigma, 1:5,000 dilution for IB 
analysis, 1 g for IP assay) from Sigma; anti-HA (MMS-101R; 1:5,000 dilution for IB 
analysis, 1 g for IP assay) from Covance; anti-H3Ac (#06-599, 1 g for ChIP assay) from 
Millipore; anti-PPAR (ab41928, 1 g for ChIP assay), anti-PGC1 (ab54481, 1 g for 
ChIP assay) and anti-HDAC3 (ab7030, 1 g for ChIP assay) from Abcam; anti-RNA 
polymerase II (MMS-126R,  1 g for ChIP assay) from Berkeley antibody company; anti-
V5 (R96025; 1:5,000 dilution for IB analysis) from Invitrogen.  
 
Statistical analysis  
The statistical analysis of different groups is realized using the Student’s unpaired t-test 
or one-way ANOVA followed by Tukey post hoc test or two-way ANOVA. SPSS 
software (IBM) was used for all analyses. 
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Hepatic nuclear receptors play critical roles in the regulation of lipid and glucose 
metabolism in response to environmental stress, including nutrient and hormonal cues 
(Wagner et al., 2011). Dysfunction of hepatic nuclear receptors is largely linked to 
metabolic diseases including obesity and type II diabetes. I found that PPAR signaling is 
a critical pathway affected by hepatic deletion of ROR. Dysregulated PPAR signaling in 
RORLKO mice results in uncontrolled lipogenesis, contributing to the development of 
hepatic steatosis and diet-induced obesity on a HFD. Furthermore, treatment of PPAR 
antagonist GW9662 decreased the susceptibility to obesity (Ma et al., 2015; Nakano et al., 
2006). Consistent with previous reports, I also observed that elevated PPARtranscriptional 
activity in RORLKO mice are down-regulated after treatment of GW9662, resulting in 
decrease of diet-induced hepatic steatosis and obesity. My data confirm that ROR is a key 
factor for the repression of PPAR signaling to protect against diet-induced hepatic steatosis 
and obesity in vivo.  
It has been widely accepted that PPAR is a major nutrient-sensing PPAR isoform to 
modulate hepatic gene expressions (Lee et al., 2014). As no substantial activation of PPAR 
has been observed in the fasted or HFD-fed RORLKO mice, I believe that ROR mainly 
controls PPAR transcriptional network to maintain hepatic homeostasis in response to 
HFD. PPAR signaling turns out to be significantly activated in HFD-fed RORLKO mice 
while increased ROR reduces PPAR transcriptional activity, providing a direct molecular 
link between ROR and PPAR. Furthermore, my data indicate that ROR regulates 
PPAR signaling through ROR-mediated HDAC3 recruitment to the PPAR target 
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promoters. Thus, ROR plays a crucial role in maintaining homeostasis of lipid metabolism 
in liver by negatively regulating PPARsignaling via HDAC3 recruitment to the PPAR 
target promoters for transcriptional repression (Fig. IV-1). 
While PPAR is a key regulator of adipogenesis and activates target genes that are 
involved in lipid storage mechanism in adipocyte to improve glucose homeostasis 
(Tontonoz and Spiegelman, 2008), the molecular mechanism of how PPAR induces 
hepatic steatosis still remains unclear. Though PPAR activation has shown to reduce blood 
glucose level and hepatic gluconeogenesis, and improve glucose tolerance (Saltiel and 
Olefsky, 1996; Way et al., 2001), several reports have shown that PPAR activation leads 
to hepatic steatosis (Mayerson et al., 2002; Musso et al., 2012). In general, the expression 
of PPAR is very low in human and mouse liver. Interestingly, the expression level of 
hepatic PPAR is significantly upregulated in obese rodent model (Vidal-Puig et al., 1996) 
and high level of PPAR in mouse liver is sufficient for the induction of adipogenic 
transformation of hepatocytes with adipose tissue-specific gene expression and lipid 
accumulation (Yu et al., 2003). These data indicate that PPAR plays a key role in 
development of hepatic steatosis. Accordingly, inhibition of PPAR signaling and hepatic 
deficiency of PPAR in ob/ob mice have shown to ameliorate fatty liver (Gavrilova et al., 
2003; Matsusue et al., 2003). Intriguingly, liver-specific PPAR deficient mice exhibit 
resistance to HFD-induced hepatic steatosis (Moran-Salvador et al., 2011). Expression of 
numerous genes involved in lipid uptake and lipid transport was remarkably decreased in 
the liver-specific PPAR-deficient mice, resulting in reduction of hepatic steatosis (Moran-
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Salvador et al., 2011). Therefore, these results strongly indicate that the PPAR signaling 
pathway is involved in diet-induced hepatic steatosis, and hepatic lipid accumulation is 
prevented by suppression of PPAR transcriptional network in the liver. 
It has been reported that ROR may compete with PPAR for the binding to PPRE (Ohoka 
et al., 2009). It is well established that PPRE contains a DR1 motif consisting of two core 
direct repeats of AGGTCA separated by a single nucleotide (Kliewer et al., 1992). Among 
nucleotides of DR1 motif, the four nucleotides immediately 5’ of DR1 motif are highly 
conserved and exhibit a consensus of A(A/T)CT. Previous study has reported that the 
binding of the DBD of PPARs to the single core binding site requires the AT-rich 5’-
extended binding site which is quite similar to the binding site for the monomer of ROR 
(Palmer et al., 1995). Thus, the similarity in the binding sequences for PPARand ROR 
appears to allow ROR to modulate PPAR signaling by competing with PPAR for binding 
to PPREs (Harding and Lazar, 1995). 
The physiological role of HDAC3 has been reported to repress hepatic steatosis. In liver-
specific Hdac3 deficient mice, little or no body weight change was observed. As HDAC3 
regulates the expression of lipogenic genes in an enzymatic activity-independent manner 
(Sun et al., 2013), fasting phase markedly promotes hepatic steatosis in liver-specific Hdac3 
deficient mice (Sun et al., 2012). An intriguing observation in this study is that ROR is 
crucial to recruit HDAC3 to repress hepatic PPAR-mediated lipogenic genes and protect 
against diet-induced hepatic steatosis and obesity. Furthermore, repressive role of ROR-
mediated HDAC3 on lipid metabolism is coupled with elevated hepatic gluconeogenesis. 
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Though hepatic HDAC3 has been shown to promote gluconeogenesis by repressing lipid 
synthesis and sequestration (Sun et al., 2012), I observed notable increase of gene 
expression involved in hepatic gluconeogenesis in HFD-fed RORLKO mice. Intriguingly, 
HDAC3 ablation upregulated hepatic expression of perilipin gene which contributes to lipid 
sequestration to ameliorate glucose tolerance (Sun et al., 2012). I also noticed that perilipin 
2, hepatic isoform of perilipin was substantially elevated in HFD-fed RORLKO mice. 
Unlike hepatic HDAC3 ablation, impaired ROR-mediated HDAC3 transcriptional 
repression led to interfere hepatic homeostasis of PPAR signaling. Therefore, disturbed 
regulatory mechanism of PPAR signaling in HFD-fed RORLKO mice would be the main 
cause of the insulin resistance and glucose intolerance. Consistent with elevated fasting 
glucose level in HFD-fed RORLKO mice, mRNA level of the rate-limiting enzyme, 
phosphoenol pyruvate carboxykinase (PEPCK), in the hepatic gluconeogenesis pathway, 
was largely elevated in HFD-fed RORLKO mice. Together, my data strongly indicate that 
physiological role of HDAC3 in the liver is to suppress PPAR transcriptional activity via 
ROR to control hepatic lipid and glucose metabolism. 
Previously, it has been reported that bile acid signaling pathway is critical to modulate 
energy expenditure in brown adipose tissue. Bile acids activates mitogen-activated protein 
kinase pathways and serve as ligands for the G protein coupled receptor (GPCR) TGR5 
(Watanabe et al., 2006). Thus, hepatic bile acid synthesis and bile acid pool size in the serum 
is critical to control metabolic rate. Bile acids induces cyclic-AMP-dependent thyroid 
hormone activating enzyme type 2 iodothyronine deiodinase (Dio2) (Watanabe et al., 2006). 
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Thus, bile acid-TGR5-cAMP-Dio2 signaling pathway in the brown adipose tissue has been 
known as a crucial mechanism to modulate energy expenditure (Watanabe et al., 2006). I 
observed that several key genes involved in bile acid synthesis were largely downregulated 
as well as serum bile acid pool size in HFD-fed RORLKO mice. Though I still do not know 
the direct mechanism of how hepatic bile acid signaling was impaired in RORLKO mice, I 
speculate that impaired hepatic bile acid synthesis would impair TGR5 activation in brown 
adipose tissue to reduce energy expenditure. 
Several of the observed metabolic alterations in the RORLKO mice are indeed different 
from those observed in Staggerer mice. For example, RORLKO mice gain significantly 
more weight than WT mice and develop hepatic steatosis when fed with HFD. However, 
Staggerer mice are protected from HFD-induced obesity and fatty liver and display 
improved insulin sensitivity (Lau et al., 2011; Lau et al., 2008). A strong difference between 
these two mouse models is their overall growth condition. RORLKO mice have no obvious 
phenotypic abnormalities under normal dietary conditions, whereas Staggerer mice suffer 
from severe growth retardation that would likely be attributed to a number of developmental 
defects. In addition, defective ROR function in other tissues including brain is likely to 
systemically affect energy intake and expenditure in the Staggerer mice, making it difficult 
to specifically dissect hepatic function of ROR. Therefore, it would be helpful to utilize 
these two mice and compare their phenotypes in certain conditions together for 
understanding of ROR function in vivo. Collectively, my data indicate that liver-specific 
ROR deficient mice were successfully developed and the utilization of the mice allowed 
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us to be able to study in vivo functions of ROR in liver more precisely by excluding the 
potential secondary effect of Staggerer mice. 
In conclusion, my data indicate that ROR requires HDAC3 to regulate PPAR signaling 
to maintain lipid homeostasis in response to over-nutrient cue. I demonstrate that major 
target of ROR in the liver is the PPAR signaling and lipid/glucose metabolism. My 
findings provide a direct link between ROR and hepatic fatty acid and glucose metabolism. 
Thus, therapeutic strategies designed to modulate ROR activity may be beneficial for the 








Figure IV-1. Graphical summary of the newly identified role of ROR that negatively 
regulated PPARsignaling via HDAC3 recruitment to the PPAR target promoters  
Proposed model for the role of ROR in hepatocyte. ROR regulates PPAR signaling via 
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국문 초록 / ABSTRACT IN KOREAN 
 
간 내 대사작용 조절에 이상이 생기면 지방간, 인슐린 저항성 및 비만을 유
도하는 것으로 알려져 있다. Retinoic acid receptor-related orphan 
receptor  (ROR) 는 소뇌 발달, 일주기 리듬 및 암을 비롯한 다양한 생물
학적 과정의 중요한 조절 자로 알려져 있다. 자연적인 Ror 돌연변이 생쥐인 
Staggerer 생쥐가 옛날부터 ROR의 생체 내 연구에 유용하게 이용되고 있
다. Staggerer 생쥐에서 고지방식을 제공하였을 때 정상 유전자형 생쥐에 비
해 체중이 적게 증대되며 지방대사를 조절하는 유전자가 간에서 발현이 감소
되어 있음이 보고되었다. 그러나 또 다른 연구에서는 ROR를 생쥐의 간에서 
과발현 시켰을 경우 오히려 반대로 지방간이 덜 진행되는 것으로 알려져 있다. 
이러한 이유는 Staggerer 생쥐가 소뇌발달이 제대로 이루어지지 않음으로써 
소뇌 위축증이 유발되어 이에 따라 운동 실조증이 일어나 정상적인 식이가 불
가능함으로써 생겨나는 부수적인 현상으로 생각된다. 즉, 아직까지는 ROR
의 대작작용에서의 역할, 특히 간에서의 역할은 정확히 밝혀지지 않았다. 이
를 해결하기 위해서는 간 특이적인 ROR의 결핍 생쥐가 필요하다. 
본 연구에서는 간 특이적인 ROR의 결핍 생쥐를 이용해서 간 내 지질 대
사를 매개하는 핵 수용체인 peroxisome proliferators-activated 
receptor  (PPAR)의 전사 활성을 ROR가 저해하여 ROR가 간 내 지질
의 항상성을 조절한다는 것을 발견했다. 간 특이적 Ror결핍 생쥐는 고지방
식 (HFD)을 제공하였을 때 정상 유전자형 생쥐에 비해 지방간, 비만 및 인
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슐린 저항성이 더 빠르고 심하게 유발됨을 확인하였다. 간 내 전체 전사체 분
석을 통해 ROR의 간 특이적인 결핍은 PPAR 신호 전달 체계의 조절에 이
상이 생겨 간 내의 포도당 대사와 지질 대사의 이상을 유발한다. ROR는 
PPAR 전사 조절 기능을 억제 하기 위해 HDAC3과 결합한 뒤 PPAR의 
표적 유전자 프로모터에 위치한다. 마지막으로, PPAR의 억제제를 이용하여 
PPAR의 기능을 저해하는 경우 고지방식을 제공한 간 특이적 Ror 결핍 생
쥐에서 간 내 대사 항상성이 현저히 회복되는 것을 관찰하였다. 이번 연구를 
통해 RORα는 PPAR 신호 전달 체계를 조절하여 간 내 지방의 항상성 조절
에 중추적인 역할을 한다는 것을 알 수 있다. 결과적으로 ROR의 활성을 조
절하는 것이 지방간 및 비만과 같은 대사 장애의 치료를 위한 새로운 치료전
략임을 본 연구를 통해 제시하였다. 
 
주요어: 
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